WO2005090603A2 - Method for diagnosing non-small cell lung cancer - Google Patents
Method for diagnosing non-small cell lung cancer Download PDFInfo
- Publication number
- WO2005090603A2 WO2005090603A2 PCT/JP2005/005613 JP2005005613W WO2005090603A2 WO 2005090603 A2 WO2005090603 A2 WO 2005090603A2 JP 2005005613 W JP2005005613 W JP 2005005613W WO 2005090603 A2 WO2005090603 A2 WO 2005090603A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- ofthe
- seq
- kifll
- nsclc
- Prior art date
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 296
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 272
- 238000000034 method Methods 0.000 title claims abstract description 202
- 150000001875 compounds Chemical class 0.000 claims abstract description 148
- 230000003993 interaction Effects 0.000 claims abstract description 40
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 claims abstract description 11
- 101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 483
- 108090000623 proteins and genes Proteins 0.000 claims description 482
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 308
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 289
- 229920001184 polypeptide Polymers 0.000 claims description 279
- 230000014509 gene expression Effects 0.000 claims description 216
- 102000004169 proteins and genes Human genes 0.000 claims description 171
- 108020004999 messenger RNA Proteins 0.000 claims description 125
- 230000027455 binding Effects 0.000 claims description 107
- 238000012360 testing method Methods 0.000 claims description 106
- 108020004459 Small interfering RNA Proteins 0.000 claims description 95
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 79
- 238000012216 screening Methods 0.000 claims description 65
- 125000003729 nucleotide group Chemical group 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 62
- 239000002773 nucleotide Substances 0.000 claims description 62
- 230000000694 effects Effects 0.000 claims description 59
- 239000013598 vector Substances 0.000 claims description 46
- 102000040430 polynucleotide Human genes 0.000 claims description 42
- 108091033319 polynucleotide Proteins 0.000 claims description 42
- 239000002157 polynucleotide Substances 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 39
- 150000007523 nucleic acids Chemical class 0.000 claims description 39
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 230000004071 biological effect Effects 0.000 claims description 36
- 239000000523 sample Substances 0.000 claims description 35
- 230000000692 anti-sense effect Effects 0.000 claims description 33
- 239000012472 biological sample Substances 0.000 claims description 32
- 108091081021 Sense strand Proteins 0.000 claims description 28
- 230000004913 activation Effects 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 26
- 230000001105 regulatory effect Effects 0.000 claims description 26
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 108020004414 DNA Proteins 0.000 claims description 22
- 238000009396 hybridization Methods 0.000 claims description 22
- 108091034117 Oligonucleotide Proteins 0.000 claims description 21
- 108091028664 Ribonucleotide Proteins 0.000 claims description 21
- 230000000295 complement effect Effects 0.000 claims description 21
- 239000002336 ribonucleotide Substances 0.000 claims description 21
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 18
- 230000007423 decrease Effects 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 17
- 108700008625 Reporter Genes Proteins 0.000 claims description 14
- 210000004899 c-terminal region Anatomy 0.000 claims description 13
- 238000004393 prognosis Methods 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 230000002103 transcriptional effect Effects 0.000 claims description 11
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 102000007469 Actins Human genes 0.000 claims description 7
- 108010085238 Actins Proteins 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 206010036790 Productive cough Diseases 0.000 claims description 5
- 108091023040 Transcription factor Proteins 0.000 claims description 5
- 210000003802 sputum Anatomy 0.000 claims description 5
- 208000024794 sputum Diseases 0.000 claims description 5
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000010837 poor prognosis Methods 0.000 claims description 4
- 108060006633 protein kinase Proteins 0.000 claims description 4
- 108010061269 protein kinase D Proteins 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002246 oncogenic effect Effects 0.000 claims description 3
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 claims description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 2
- 108091078243 Rho family Proteins 0.000 claims description 2
- 102000042463 Rho family Human genes 0.000 claims description 2
- 102000014384 Type C Phospholipases Human genes 0.000 claims description 2
- 108010079194 Type C Phospholipases Proteins 0.000 claims description 2
- 230000010307 cell transformation Effects 0.000 claims description 2
- 210000004292 cytoskeleton Anatomy 0.000 claims description 2
- 230000012202 endocytosis Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 231100000590 oncogenic Toxicity 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 230000008521 reorganization Effects 0.000 claims description 2
- 230000004960 subcellular localization Effects 0.000 claims description 2
- 230000008093 supporting effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 41
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 230000004570 RNA-binding Effects 0.000 claims 1
- -1 GHSR1b Proteins 0.000 abstract description 5
- 101001008953 Homo sapiens Kinesin-like protein KIF11 Proteins 0.000 abstract description 5
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 abstract description 5
- 101000591385 Homo sapiens Neurotensin receptor type 1 Proteins 0.000 abstract description 4
- 102000017921 NTSR1 Human genes 0.000 abstract description 3
- 108010008599 Forkhead Box Protein M1 Proteins 0.000 abstract 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 157
- 108010021512 neuromedin U Proteins 0.000 description 107
- 102100038813 Neuromedin-U Human genes 0.000 description 103
- 206010028980 Neoplasm Diseases 0.000 description 75
- 241000282414 Homo sapiens Species 0.000 description 62
- 201000011510 cancer Diseases 0.000 description 54
- 239000004055 small Interfering RNA Substances 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 48
- 108050007316 Rab35 Proteins 0.000 description 37
- 102000028593 Rab35 Human genes 0.000 description 37
- 239000012091 fetal bovine serum Substances 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 238000011282 treatment Methods 0.000 description 36
- 102000005962 receptors Human genes 0.000 description 35
- 208000020816 lung neoplasm Diseases 0.000 description 34
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 31
- 239000002299 complementary DNA Substances 0.000 description 31
- 201000005202 lung cancer Diseases 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- 238000003556 assay Methods 0.000 description 26
- 230000012010 growth Effects 0.000 description 26
- 101800002021 Neuromedin-U-25 Proteins 0.000 description 25
- 108090000994 Catalytic RNA Proteins 0.000 description 24
- 102000053642 Catalytic RNA Human genes 0.000 description 24
- 108091092562 ribozyme Proteins 0.000 description 24
- 239000012980 RPMI-1640 medium Substances 0.000 description 23
- 230000000875 corresponding effect Effects 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 239000000427 antigen Substances 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 22
- 238000002493 microarray Methods 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 210000000612 antigen-presenting cell Anatomy 0.000 description 21
- 238000001114 immunoprecipitation Methods 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- 108700020796 Oncogene Proteins 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 230000032258 transport Effects 0.000 description 18
- 238000000018 DNA microarray Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 239000000074 antisense oligonucleotide Substances 0.000 description 15
- 238000012230 antisense oligonucleotides Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000006698 induction Effects 0.000 description 15
- 210000004443 dendritic cell Anatomy 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000014616 translation Effects 0.000 description 14
- 230000005809 anti-tumor immunity Effects 0.000 description 13
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 12
- 101000604177 Homo sapiens Neuromedin-U receptor 2 Proteins 0.000 description 12
- 238000000134 MTT assay Methods 0.000 description 12
- 101800001814 Neurotensin Proteins 0.000 description 12
- 102400001103 Neurotensin Human genes 0.000 description 12
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 11
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 11
- 102100037924 Insulin-like growth factor 2 mRNA-binding protein 1 Human genes 0.000 description 11
- 101710126181 Insulin-like growth factor 2 mRNA-binding protein 1 Proteins 0.000 description 11
- 231100000002 MTT assay Toxicity 0.000 description 11
- 102000029749 Microtubule Human genes 0.000 description 11
- 108091022875 Microtubule Proteins 0.000 description 11
- 102100038814 Neuromedin-U receptor 2 Human genes 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 210000004688 microtubule Anatomy 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 229920000936 Agarose Polymers 0.000 description 10
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 10
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 102100039556 Galectin-4 Human genes 0.000 description 10
- 101800001586 Ghrelin Proteins 0.000 description 10
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000004807 localization Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 206010041823 squamous cell carcinoma Diseases 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 101710150697 Inositol monophosphatase 1 Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 230000008045 co-localization Effects 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 239000013074 reference sample Substances 0.000 description 9
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000010396 two-hybrid screening Methods 0.000 description 9
- LOBCDGHHHHGHFA-LBPRGKRZSA-N (S)-monastrol Chemical compound CCOC(=O)C1=C(C)NC(=S)N[C@H]1C1=CC=CC(O)=C1 LOBCDGHHHHGHFA-LBPRGKRZSA-N 0.000 description 8
- 241000796533 Arna Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 206010041067 Small cell lung cancer Diseases 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 208000037841 lung tumor Diseases 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001082 somatic cell Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 7
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 7
- 102000000393 Ghrelin Receptors Human genes 0.000 description 7
- 108010016122 Ghrelin Receptors Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000003305 autocrine Effects 0.000 description 7
- 230000036952 cancer formation Effects 0.000 description 7
- 231100000504 carcinogenesis Toxicity 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000004758 lung carcinogenesis Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000005253 yeast cell Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 6
- 102000010638 Kinesin Human genes 0.000 description 6
- 108010063296 Kinesin Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102000004389 Ribonucleoproteins Human genes 0.000 description 6
- 108010081734 Ribonucleoproteins Proteins 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000009918 complex formation Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000010865 video microscopy Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101001024391 Homo sapiens Neuromedin-U receptor 1 Proteins 0.000 description 5
- 102100035314 Neuromedin-U receptor 1 Human genes 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 102100022056 Serum response factor Human genes 0.000 description 5
- 101710120037 Toxin CcdB Proteins 0.000 description 5
- 241000269370 Xenopus <genus> Species 0.000 description 5
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 208000003849 large cell carcinoma Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000010859 live-cell imaging Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 4
- 101000583189 Homo sapiens Plakophilin-4 Proteins 0.000 description 4
- 101710144867 Inositol monophosphatase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108090000189 Neuropeptides Proteins 0.000 description 4
- 102100030365 Plakophilin-4 Human genes 0.000 description 4
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 108060002430 dynein heavy chain Proteins 0.000 description 4
- 102000013035 dynein heavy chain Human genes 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 235000013902 inosinic acid Nutrition 0.000 description 4
- 230000025563 intercellular transport Effects 0.000 description 4
- 210000005265 lung cell Anatomy 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000017066 negative regulation of growth Effects 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 206010053759 Growth retardation Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001136954 Homo sapiens Proteasome subunit beta type-7 Proteins 0.000 description 3
- 101000692225 Homo sapiens Selenocysteine insertion sequence-binding protein 2 Proteins 0.000 description 3
- 101000837443 Homo sapiens T-complex protein 1 subunit beta Proteins 0.000 description 3
- 101710150707 Inositol monophosphatase 2 Proteins 0.000 description 3
- 102100037919 Insulin-like growth factor 2 mRNA-binding protein 2 Human genes 0.000 description 3
- 101710126176 Insulin-like growth factor 2 mRNA-binding protein 2 Proteins 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102100037170 Phosphate carrier protein, mitochondrial Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100035763 Proteasome subunit beta type-7 Human genes 0.000 description 3
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108091006710 SLC25A3 Proteins 0.000 description 3
- 102100026077 Selenocysteine insertion sequence-binding protein 2 Human genes 0.000 description 3
- 101710111748 Signal peptide peptidase-like 3 Proteins 0.000 description 3
- 102100028679 T-complex protein 1 subunit beta Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000012760 immunocytochemical staining Methods 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000670 ligand binding assay Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 102000040811 transporter activity Human genes 0.000 description 3
- 108091092194 transporter activity Proteins 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 101150087690 ACTB gene Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- OHOQEZWSNFNUSY-UHFFFAOYSA-N Cy3-bifunctional dye zwitterion Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C2=CC=C(S(O)(=O)=O)C=C2C(C)(C)C1=CC=CC(C(C1=CC(=CC=C11)S([O-])(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O OHOQEZWSNFNUSY-UHFFFAOYSA-N 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108091005942 ECFP Proteins 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 2
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100028603 Glutaryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101150009006 HIS3 gene Proteins 0.000 description 2
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 2
- 101001058943 Homo sapiens Glutaryl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 2
- 101000882884 Homo sapiens Mitochondrial tRNA methylthiotransferase CDK5RAP1 Proteins 0.000 description 2
- 101001108862 Homo sapiens Nucleoporin NUP188 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000283953 Lagomorpha Species 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 102100038450 Mitochondrial tRNA methylthiotransferase CDK5RAP1 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 102100021530 Nucleoporin NUP188 Human genes 0.000 description 2
- 102000016979 Other receptors Human genes 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108050005900 Signal peptide peptidase-like 2a Proteins 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 2
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000008568 cell cell communication Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 230000006690 co-activation Effects 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003976 gap junction Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000000020 growth cone Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000009640 growth promoting pathway Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000010397 one-hybrid screening Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000003160 two-hybrid assay Methods 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000024137 vesicle transport along microtubule Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical group NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000031638 Body Weight Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282692 Catarrhini Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101001008952 Dictyostelium discoideum Kinesin-related protein 11 Proteins 0.000 description 1
- 102000019205 Dynactin Complex Human genes 0.000 description 1
- 108010012830 Dynactin Complex Proteins 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710202200 Endolysin A Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000195619 Euglena gracilis Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108091027874 Group I catalytic intron Proteins 0.000 description 1
- 108091029499 Group II intron Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 102100028909 Heterogeneous nuclear ribonucleoprotein K Human genes 0.000 description 1
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 1
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 101100215371 Homo sapiens ACTB gene Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000599782 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 3 Proteins 0.000 description 1
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101000981685 Homo sapiens Protein Lines homolog 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 101710126182 Insulin-like growth factor 2 mRNA-binding protein 3 Proteins 0.000 description 1
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100029050 Neuropeptide FF receptor 2 Human genes 0.000 description 1
- 101710105958 Neuropeptide FF receptor 2 Proteins 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 102100033986 Neurotensin receptor type 1 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241000282515 Papio hamadryas Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 101000622060 Photinus pyralis Luciferin 4-monooxygenase Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100024087 Protein Lines homolog 1 Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101001060868 Strawberry mild yellow edge-associated virus Helicase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 101500022167 Youcai mosaic virus Replicase small subunit Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000031376 exit from mitosis Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003626 gastrointestinal polypeptide Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000053563 human MYC Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 238000000370 laser capture micro-dissection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 102000033952 mRNA binding proteins Human genes 0.000 description 1
- 108091000373 mRNA binding proteins Proteins 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 238000007694 polyacrylamide gel isoelectric focusing Methods 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108091029536 tRNA precursor Proteins 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- WQAJKOXBERTWBK-UHFFFAOYSA-N verdine Natural products CC1CNC2C(C1)OC3(CCC4C5CCC6(O)CC(O)CC(O)C6(C)C5C(=O)C4=C3C)C2C WQAJKOXBERTWBK-UHFFFAOYSA-N 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to the field of biological science, more specifically to the field of cancer therapy and diagnosis.
- the invention relates to methods of diagnosing non-small cell lung cancers using genes, KIF11, GHSRlb, NTSRl, and FOXMl, that show elevated expression in such cancerous cells.
- Lung cancer is one ofthe most commonly fatal human tumors. Many genetic alterations associated with the development and progression of lung cancer have been reported. Although genetic changes can aid prognostic efforts and predictions of metastatic risk or response to certain treatments, information about a single or a limited number of molecular markers generally fails to provide satisfactory results for clinical diagnosis of non-small cell lung cancer (NSCLC) (Mitsudomi et al., Clin Cancer Res 6: 4055-63 (2000); Niklinski et al, Lung Cancer. 34 Suppl 2: S53-8 (2001); Watine, BMJ320: 379-80 (2000)). NSCLC is by far the most common form, accounting for nearly 80% of lung tumors (Society, A.C. Cancer Facts and Figures 2001 (2001)).
- NSCLC non-small cell lung cancer
- TNTs tunneling nanotubes
- RNA-binding proteins and motor proteins like kinesin and dynein within mammalian somatic cells, as well as intercellular mRNA transport in mammalian germ cells (Brendza, R.P. et al, Science 289, 2120-2122 (2000); Chennathukuzhi, V. et al, Proc. Natl. Acad. Sci. USA 100, 15566-15571 (2003); Villace, P. et al, Nucleic Acids
- Beta actin (ACTB) mRNA is localized at the leading lamellae of chicken embryo fibroblasts (CEFs) (Lawrence, J.B., Singer, R.H.
- ACTB mRNA The localization of ACTB mRNA is dependent on the zipcode, a cis-acting element located in the 3' UTR ofthe mRNA (Kislauskis, E.H. et al, J. Cell Biol. 123: 165-172 (1993)).
- the trans-acting factor, zipcode binding protein 1 (ZBPl) was affinity purified with the zipcode of ACTB mRNA (Ross, A.F. et al, Mol. Cell Biol. 17, 2158-2165 (1997)).
- ZBPl family members are expressed in germ embryonic fibroblasts and in several types of cancer (Mueller-Pillasch, F. et al, Oncogene 14: 2729-2733 (1997); Mueller, F. et al, Br. J. Cancer 88; 699-701 (2003)).
- ZBPl-like proteins contain two RNA-recognition motifs (RRMs) at the NH2-terminal part ofthe protein and four hnRNP K homology (KH) domains at the COOH-terminal end.
- RRMs RNA-recognition motifs
- KH hnRNP K homology
- KOC1 (alias IGF-II mRNA-binding protein 3: IMP-3) is one ofthe IMPs (IMP-1, IMP-2, and IMP-3), which belong to the ZBPl family members and exhibit multiple attachments to IGF-II leader 3 mRNA and the reciprocally imprinted HI 9 RNA (Mueller-Pillasch, F. et al, Oncogene 14: 2729-2733 (1997)). Although KOC1 was initially reported to be over-expressed in pancreatic cancer (Mueller-Pillasch, F. et al, Oncogene 14: 2729-2733
- KOC1 is orthologous to the Xenopus Ngl R ⁇ A-binding protein (NglRBP/Vera), which mediates the localization of Ngl mR ⁇ Ato the vegetal pole ofthe oocyte during oocyte maturation, and IMP-1 is orthologous to the ZBPl .
- IMP is mainly located at the cytoplasm and its cellular distribution ranges from a distinct concentration in perinuclear regions and lamellipodia to a completely delocalized pattern.
- KIFl 1 (alias EG5) is a member of kinesin family, and plays a role in establishing and/or determining the stability of specific microtuble arrays that form during cell division. This role may encompass the ability of KIFl 1 to influence the distribution of other protein components associated with cell division (Whitehead, CM., Rattner, J.B. J. Cell Sci. Ill: 2551-2561 (1998); Mayer, T.U.
- NMU is a neuropeptide that was first isolated from porcine spinal cord. It has potent activity on smooth muscles (Minamino, N. et al, Biochem. Biophys. Res. Commun. 130: 1078-1085 (1985); Domin, J. et al, Biochem. Biophys. Res. Commun. 140: 1127-1134 (1986); Conlon, J.M. et al, J. Neurochem. 51 : 988-991 (1988); Minamino, N. et al, Biochem. Biophys. Res. Commun. 156: 355-360 (1988); Domin, J. et al, J. Biol. Chem.
- NMU NMU is distributed predominantly in the gastrointestinal tract and central nervous system (Howard, A.D. et al, Nature 406: 70-74 (2000); Funes, S. et al, Peptides 23: 1607-1615 (2002)).
- NMU neuropeptides function peripherally as paracrine and autocrine factors to regulate diverse physiologic processes and act as neurotransmitters or neuromodulators in the nervous system.
- receptors that mediate signaling by binding neuropeptides are members of the superfamily of G protein-coupled receptors (GPCRs) having seven fransmembrane-spanning domains.
- NMUIR Two known receptors for NMU, NMUIR and NMU2R, show a high degree of homology to other neuropeptide receptors such as GHSR and NTSRl, for which the corresponding known ligands are Ghrelin (GHRL) and neurotensin (NTS), respectively.
- NMUIR FM3/GPR66
- NMU2R FM4
- Fujii R. et al, J. Biol. Chem. 275: 21068-21074 (2000); Howard, A.D. et al, Nature 406: 70-74 (2000); Funes, S.
- NMU neuropeptide
- a C-terminal asparaginamide structure and the C-terminal hepatapeptide core of NMU protein are essential for its contractile activity in smooth-muscle cells (Westfall, T.D. et al, J. Pharmacol. Exp. Then 301: 987-992 (2002); Austin, C. J. Mol. Endocrinol. 14: 157-169 (1995)).
- NMU acts at the hypothalamic level to inhibit food intake; therefore this protein might be a physiological regulator of feeding and body weight (Howard, A.D. et al, Nature 406: 70-74 (2000); Maggi, CA. et al, Br. J. Pharmacol.
- FTIs farnesyltransferase
- a tyrosine kinase inhibitor, STI-571, which selectively inactivates bcr-abl fusion proteins, has been developed to treat chronic myelogenous leukemias wherein constitutive activation of bcr-abl tyrosine kinase plays a crucial role in the transformation of leukocytes.
- Agents of these kinds are designed to suppress oncogenic activity of specific gene products (Fujita et al, Cancer Res. 61:7722-6 (2001)). Therefore, gene products commonly up-regulated in cancerous cells may serve as potential targets for developing novel anti-cancer agents.
- CTLs cytotoxic T lymphocytes
- TAAs tumor-associated antigens
- TAAs are now in the stage of clinical development as targets of immunotherapy. TAAs discovered so far include MAGE (van der Bruggen et al, Science 254: 1643-7 (1991)), gplOO (Kawakami et al, J. Exp. Med. 180: 347-52 (1994)), SART (Shichijo et al, J. Exp. Med. 187: 277-88 (1998)), and NY-ESO-1 (Chen et al, Proc. Natl. Acad. Sci. USA 94: 1914-8 (1997)).
- TAAs abundantly expressed in cancer cells, and at the same time which expression is restricted to cancer cells would be promising candidates as immunotherapeutic targets. Further, identification of new TAAs inducing potent and specific antitumor immune responses is expected to encourage clinical use of peptide vaccination strategy in various types of cancer (Boon and can der Bruggen, J. Exp. Med. 183: 725-9 (1996); van der Bruggen et al, Science 254: 1643-7 (1991); Brichard et al, J. Exp. Med.
- PBMCs peripheral blood mononuclear cells
- HLA-A24 and HLA-A0201 are one ofthe popular HLA alleles in Japanese, as well as Caucasian (Date et al, Tissue Antigens Al: 93-101 (1996); Kondo et al, J. Immunol. 155: 4307-12 (1995); Kubo et al, J. Immunol. 152: 3913-24 (1994); Imanishi et al, Proceeding ofthe eleventh International Histocompatibility Workshop and Conference Oxford University Press, Oxford, 1065 (1992); Williams et al, Tissue Antigen 49: 129 (1997)).
- antigenic peptides of cancers presented by these HLAs may be especially useful for the treatment of cancers among Japanese and Caucasian.
- the present invention features a method of diagnosing or determining a predisposition to non-small cell lung cancer (NSCLC) in a subject by determining an expression level of a non-small cell lung cancer-associated gene that is selected from the group of KIFll, GHSRlb, NTSRl, and FOXMl in a patient derived biological sample.
- NSCLC non-small cell lung cancer
- An increase ofthe expression level of any ofthe genes compared to a normal control level ofthe genes indicates that the subject suffers from or is at risk of developing NSCLC.
- the invention also provides methods of providing a prognosis of a patient diagnosed with NSCLC. In particular, the methods involve detecting expression of KOCl, KIFll, or KOCl in combination with expression of KIF 11.
- a "normal control level” indicates an expression level of any ofthe genes detected in a normal, healthy individual or in a population of individuals known not to be suffering from NSCLC.
- a control level is a single expression pattern derived from a single reference population or from a plurality of expression patterns.
- the "control level” is an expression level ofthe gene detected in an individual or a population of individuals whose background ofthe disease state is known (i.e., cancerous or non-cancerous).
- the control level may be determined base on the expression level ofthe gene in a normal, healthy individual, in a population of individuals known not to be suffering from NSCLC, a patient of NSCLC or a population ofthe patients.
- the control level corresponding to the expression level ofthe gene in a patient of non-small cell lung cancer or a population ofthe patients is referred to as "NSCLC control level".
- the control level can be a database of expression patterns from previously tested cells.
- An increase in the expression level of any one ofthe genes of KIFll, GHSRlb, NTSRl, and FOXMl detected in a test biological sample compared to a normal control level indicates that the subject (from which the sample was obtained) suffers from NSCLC.
- the expression level of any one or all ofthe genes in a biological sample may be compared to an NSCLC control level ofthe same gene(s). Gene expression is increased or decreased 10%, 25%, 50% or more compared to the control level.
- gene expression is increased or decreased 1, 2, 5 or more fold compared to the control level.
- Expression is determined by detecting hybridization, e.g., on a ' chip or an array, of an NSCLC gene probe to a gene transcript of a patient-derived biological sample.
- the patient-derived biological sample may be any sample derived from a subject, e.g., a patient known to or suspected of having NSCLC.
- the biological sample may be tissue containing sputum, blood, serum, plasma or lung cell.
- the invention also provides a non-small cell lung cancer reference expression profile comprising a pattern of gene expression levels of two or more genes selected from the group of KIFll, GHSRlb, NTSRl, and FOXMl.
- the invention also provides a kit comprising two or more detection reagents which detects the expression of one or more of genes selected from the group of KIFll, GHSRlb, NTSRl, and FOXMl (e.g., via detecting mRNA and polypeptide). Also provided is an array of polynucleotides that binds to one or more ofthe genes selected from the group of KIFll, GHSRlb, NTSRl , and FOXMl .
- the kits of the invention may also comprise reagents used to detect the expression of KIFll and KOCl to be used for the prognosis of NSCLC.
- the invention also provides kits for the detection of compounds that regulate RNA transporting activity.
- kits may comprise a cell expressing a KIFl 1 polypeptide, or functional equivalent, a KOCl polypeptide, or functional equivalent, and RNA to be transported, and DCTNl .
- the kits ofthe invention may also be used to screen for compounds for treating or preventing NSCLC.
- the kits may comprise a KOCl polypeptide, or functional equivalent, and an RNA that is bound by the KOCl polypeptide or functional equivalent.
- the invention further provides methods of identifying compounds that inhibit the expression level of an NSCLC-associated gene (KIFll, GHSRlb, NTSRl or FOXMl) by contacting a test cell expressing an NSCLC-associated gene with a test compound and determining the expression level ofthe NSCLC-associated gene.
- the test cell may be an NSCLC cell.
- a decrease ofthe expression level compared to a normal control level ofthe gene indicates that the test compound is an inhibitor ofthe expression or function ofthe NSCLC-associated gene. Therefore, if a compound suppresses the expression level of KIFll, GHSRlb, NTSRl or FOXMl compared to a control level, the compound is expected to reduce a symptom of NSCLC.
- the present invention provides a method of screening for a compound for treating or preventing NSCLC.
- the method includes contacting a polypeptide selected from the group of KIFll, GHSRlb, NTSRl, and FOXMl with atest compound, and selecting the test compound that binds to or suppresses the biological activity ofthe polypeptide.
- the invention further provides a method of screening for a compound for treating or preventing NSCLC, which includes the steps of contacting a test compound with a cell that expresses KIFll, GHSRlb, NTSRl or FOXMl protein or introduced with a vector comprising the transcriptional regulatory region of KIFl 1, GHSRlb, NTSRl or FOXMl gene upstream of a reporter gene, and then selecting the test compound that reduces the expression level ofthe KIFll, GHSRlb, NTSRl or FOXMl protein or protein encoded by the reporter gene.
- the test compound that suppresses the biological activity or the expression level compared to a control level is expected to reduce a symptom of NSCLC.
- the present invention provides a method of screening for a compound for treating or preventing NSCLC wherein the binding between KIFll and KOCl, or GHSRlb or NTSRl and NMU is detected.
- Compounds that inhibit the binding between KIF 11 and KOC 1 , or GHSRlb or NTSRl and NMU are expected to reduce a symptom of NSCLC.
- a complex of these two molecules in lung tumors was able to bind mRNAs encoding proteins known to function in intercellular adhesion, cancer-cell progression, and oncogenesis, and transport them to neighboring cells through ultrafine intercellular structures.
- KOCl binds to KIFl 1 at the RRM domain in the N-terminal region of KOCl .
- evidence provided here shows inhibition of their binding by dominant-negative KOCl mutants effectively suppressed growth of NSCLC cells in vitro.
- KOCl fragments (or nucleic acids encoding them) comprising the RRM domains of KOCl can be used as dominant negative fragments to suppress cell proliferation and thus treat cancer.
- the KOCl fragment may comprise the ribonucleoprotein K-homologous (KH) domain.
- the invention also provides methods of identifying polypeptides and other compounds that modulate RNA transport activity.
- a polypeptide can be tested for RNA transporting activity by contacting the polypeptide with a KIFll polypeptide or a functional equivalent thereof with an RNA that can be transported by KIFll under conditions suitable for transportation of RNA.
- agents that modulate RNA transporting activity can be tested by contacting a test agent with a KIFl 1 polypeptide or a functional equivalent thereof with an RNA that can be transported by KIFl 1 under conditions suitable for transportation of RNA.
- Test agents useful for treating NSCLC by testing the agents for the ability to inhibit binding between a KOC 1 polypeptide, or a functional equivalent, and an RNA that is bound by KOCl or the complex of KOCl and KIFll.
- Immunohistochemical analysis of lung-cancer tissue microarrays demonstrated that transactivation of KOCl and KIFll was significantly associated with poor prognosis of lung-cancer patients. Methods for treating or preventing NSCLC and compositions to be used for such methods are also provided.
- Therapeutic methods include a method of treating or preventing NSCLC in a subject by administering to the subject a composition of an antisense, short interfering RNA (siRNA) or a ribozyme that reduce the expression of KIFll, GHSRlb, NTSRl or FOXMl gene, or a composition comprising an antibody or fragment thereof that binds and suppresses the function of a polypeptide encoded by the gene.
- the compositions ofthe invention may also comprise a dominant negative KOCl mutant (or nucleic acids encoding it) comprising a KOCl fragment that contains one or more RRM domains and/or KH domains of KOCl .
- the invention also includes vaccines and vaccination methods.
- a method of treating or preventing NSCLC in a subject is carried out by administering to the subject a vaccine containing a polypeptide encoded by KIFll, GHSRlb, NTSRl or FOXMl gene, or an immunologically active fragment ofthe polypeptide.
- An immunologically active fragment is a polypeptide that is shorter in length than the full-length naturally-occurring protein and which induces an immune response upon introduction into the body.
- an immunologically active fragment includes a polypeptide of at least 8 residues in length that stimulates an immune cell such as a T cell or a B cell in vivo.
- Immune cell stimulation can be measured by detecting cell proliferation, elaboration of cytokines (e.g., IL-2) or production of antibody.
- Other therapeutic methods include those wherein a compound selected by the screening method ofthe present invention is administered.
- double-stranded molecules that comprise a sense strand and an antisense strand.
- the sense strand comprises a ribonucleotide sequence corresponding to a target sequence comprised within the mRNA of a KIFll, GHSRlb, NTSRl or FOXMl gene, and the antisense strand is a complementary sequence to the sense strand.
- Such double-stranded molecules ofthe present invention can be used as siRNAs against KIFll, GHSRlb, NTSRl or FOXMl gene. Furthermore, the present invention relates to vectors encoding the double-stranded molecules ofthe present invention.
- the present application also provides a composition for treating and/or preventing NSCLC using any ofthe antisense polynucleotides or siRNAs against KIFl 1 , GHSRlb, NTSRl or FOXMl gene, or an antibody that binds to a polypeptide encoded by KIFl 1, GHSRlb, NTSRl or FOXMl gene.
- Other compositions include those that contain a compound selected by the screening method ofthe present invention as an active ingredient.
- Figure. 1 shows photographs confirming the relationship between KOCl and KIFll.
- (a) depicts the result of co-immunoprecipitation of KOCl and KIFl 1 confirming the interaction between KOC 1 and KIF 11.
- A549 cells were transiently co-transfected with Flag-tagged KIFll and myc-tagged KOCl, immunoprecipitated with anti-Flag M2 agarose, and subsequently immunoblotted with anti-myc antibody.
- the cells were immunoprecipitated with anti-myc agarose and immunoblotted with anti-Flag M2 antibody.
- a band corresponding to the immunoblotted protein was found only when both constructs were co-transfected.
- (b) depicts the result of immunocytochemical staining showing the co-localization of KOCl and KIFll.
- COS-7 cells were transiently transfected with FLAG-tagged KIFll and myc-tagged KOCl, and their co-localization was detected mainly in the cytoplasm using FITC-labeled anti-FLAG antibody and rhomamine-labeled anti-myc antibody.
- (c) depicts the result of reciprocal co-immunoprecipitation of endogenous KOCl and KIF 11 from extracts of lung-cancer cell lines A549 and LC319.
- (upper panel) Western-blot analysis of both cell extracts immunoprecipitated with anti-KOCl antibodies, with KIFl 1 protein detected in the immunoprecipitate.
- FIG.2 shows photographs confirming co-activation of KOCl and KIFll in lung tumors and normal tissues.
- (a) depicts the result of QRT-PCR examining expression of KOCl and KIFll in clinical samples of NSCLC and corresponding normal lung tissues. Y-axis indicates the relative expression rate ofthe two genes (KOCl or KIFll I ACTB).
- (b) depicts the result of QRT-PCR examining expression of KOCl and KIFll among 20 lung-cancer cell lines.
- (c) depicts the result of Northern-blot analysis detecting expression of KOCl and KIFll in normal human tissues.
- FIG. 3 shows photographs corrfirming the relationship between KOCl and KIFll.
- (a) shows schematic drawing of five KOCl deletion mutants lacking either or both ofthe terminal regions, with N- and C-terminals tagged with FLAG and HA respectively.
- KH ribonucleoprotein K-homologous domain.
- (b) depicts the result of immunoprecipitation experiments for identification ofthe region of KOCl that binds to KIFll.
- the KOC1DEL4 and KOC1DEL5 constructs, which lacked two RNA-recognition motifs, (RRM) did not retain any appreciable ability to interact with endogenous KIF 11.
- Figure. 4 shows photographs confirming the relationship between KOCl and KOC 1 -associated mRNAs.
- (a) depicts the result of Western blotting with immunoprecipitated KOCl deletion mutants and DIG-labeled RAB35 full length mRNA for identification ofthe mRNA-binding region in KOC 1.
- (b) depicts the result of Northwestern with immunoprecipitated KOCl deletion mutants and DIG-labeled RAB35 full length mRNA for identification ofthe mRNA-binding region in KOCl.
- the KOC1DEL3 and KOC1DEL5 did not bind to any of these mRNAs, and the KOC1DEL4, which is a construct with the four KH domains only, showed similar binding affinities for mRNAs to the KOC1DEL2, a construct without C-terminal two KH domains.
- FIG. 1 depicts the result of IP-RT-PCR for confirmation of ff -microarray and the ability of various KOCl deletion mutants transfected into A549 cells to bind directly to representative eight endogenous mRNAs (CCT2, SBP2, SLC25A3, RAB35, PSMB7, GL, PKP4, and WINS1) among 55 candidate genes (see Table2).
- Figure.5 shows photographs showing movement of KOCl -KIF 11 -mRNA ribonuleoprotein complexes in living cultured mammalian cells.
- (a) are photographs showing transport of the KOC 1 -KIF 11 protein complex. Small particles that expressed fluorescent cyan (ECFP) KOCl and yellow (EYFP) KIFll proteins were co-localized, and transferred together between connected COS-7 cells through ultrafine intercellular structures (arrows)
- (b) are photographs showing transport of KOC1-RAB35 mRNARNP complex from one COS-7 cell that contains a high level of KOC1-RNP complex (cell A) to another cell with a lower level ofthe complex (stained simply with CellTracker (blue); cell B). Small particles of KOCl (green)-RAB35 mRNA (red) complex as well as KOCl particles (green) were transferred from cell A to cell B through ultrafine intercellular structures (arrows).
- Figure. 6 shows photographs showing localization of KOCl -KIF 11 -mRNA ribonuleoprotein complexes.
- (a) depicts the result of immunoprecipitation of cell extracts from A549 and LC319 confirming of direct interaction between endogenous KIFll and DCTNl (upper and lower panels).
- Figure. 7 shows photographs showing translation of KOCl -associated mRNAs transported into the recipient cells.
- (a) are photographs showing translation of mRNA transported into the recipient cells monitored by in situ hybridization.
- (b) are photographs showing protein synthesis based on transported mRNA in receiving cell. Constructs with Ml length RAB35 mRNA fused in frame to a myc tag sequence (upper panel).
- FIG. 8 shows the effect of KIFll siRNAs on cells.
- (a) depicts the inhibition on the growth of NSCLC cells by siRNAs against KIFl 1.
- (b) depicts the viability of A549 cells in response to si-KIF#l, #2, #3, EGFP, LUC, or SC, evaluated by triplicate MTT assays.
- Figure. 9 shows the effect of KOCl dominant-negative on cells.
- (d) depicts the results of immunoprecipitation detecting reduction ofthe complex formation between endogenous KOCl and KIFll in A549 cells that were transfected with the KOC1DEL2 construct.
- (e) depicts the results of immunoprecipitation detecting interaction ofthe KOC1DEL2 with endogenous KIFll in A549 cells.
- (f) depicts the viability of A549 cells in response to dose-dependent dominant-negative effect of KOC1DEL2 evaluated by triplicate MTT assays.
- X-axis indicates dosage of KOC1DEL2 plasmid-DNA ( ⁇ g) transfected into A549 cells in individual assays.
- Figure. 10 shows the effect of RAB35 siRNAs on cells.
- (a) depicts the result of semi-quantitative RT-PCR analyzing mRNA knock-down effect in response to si-RAB35 or control siRNAs in A549 cells.
- (b) show results of MTT assays of A549 cells transfected with specific siRNA or control plasmids (EGFP, Scramble, or Luciferase). Error bars represent the standard deviation of triplicate assays.
- Figure. 11 shows association of KOCl and KIFll over-expression with worse outcomes in NSCLC.
- (a) depicts the results of immunohistochemical evaluation of representative samples from surgically-resected SCC tissues, using anti-KOCl (left) and anti-KIFll (right) polyclonal antibodies on tissue microarrays (X200).
- (b) depicts the results of Kaplan-Meier analysis of tumor-specific survival times according to KOCl expression (left panel) and KIFll expression (right panel) on tissue microarrays.
- Figure. 12 is schematic model for the mechanism of intracellular and cell-to-cell mRNA transport by KOC 1 -KIF 11 -DCTNl complexes on microtubules.
- the KOCl ribonucleoprotein complex transports KOCl -associated mRNAs through the structure of microtubules within or between mammalian somatic cells.
- This model implies that proliferating cancer-cells may communicate actively by engaging this molecular complex in a system that transports mRNAs critical for cancer growth or progression from one cell to another
- Fig. 8 shows the relationship between NMU and GHSRlb NTSRl .
- Figure. 13 (a) shows the result of semiquantitative RT-PCR analysis depicting the expression of NMU, candidate receptors, and their known ligands detected in NSCLC cell lines. (b) shows GHSRlb expression in normal human tissues.
- (c) depicts the result of immunocytochemical staining using FITC-labeled anti-FLAG antibody showing the co-localization of NMU and GHSRlb/NTSRl on the cell surface of COS-7 cells that were transiently transfected with FLAG-tagged GHSRlb or NTSRl.
- (d) depicts the interaction of NMU with GHSRlb/NTSRl .
- COS-7 cells were transiently transfected with the same vectors, and binding of rhodamine-labeled NMU-25 to the cell surface was detected by flow cytometry.
- ligand/cell combinations were prepared: 1) non-transfected COS-7 cells; 2) NMU-25-rhodarnine vs non-transfected COS-7 cells; and 3) COS-7 cells transfected only with GHSRlb or NTSRl .
- (e) depicts the results of receptor-ligand binding assay using the LC319 and PC- 14 cells treated with NMU-25.
- (f) depicts cAMP production of NMU-treated NSCLC cells.
- Figure. 14 shows the effect of siRNAs on cells.
- (a) depicts the inhibition on the growth of NSCLC cells by siRNAs against GHSRlb and NTSRl . Expression of GHSR or NTSRl in response to specific siRNAs (si-GHSR or si-NTSRl) or control siRNAs (EGFP, LUC, SCR) in A549 and LC319 cells were analyzed by semiquantitative RT-PCR.
- si-GHSR or si-NTSRl specific siRNAs
- EGFP EGFP, LUC, SCR
- Figure. 15 shows validation of candidate downstream genes of NMU.
- (a) depicts time-dependent reduction of NMU transcript by si-NMU.
- (b) depicts the result of semiquantitative RT-PCR experiments of mRNAs from LC319 cells treated with si-NMU, with gene-specific primers confirming time-dependent reduction of candidate downstream target gene expression.
- (c) depicts the result of semiquantitative RT-PCR using mRNAs from LC319 cells incubated with NMU-25 or BSA (control) (100 ⁇ M) detecting induction of FOXMl as the candidate downstream target gene of NMU.
- Figure. 16 shows the effect of FOXMl siRNAs on cells.
- (a) depicts inhibition of growth of NSCLC cells by siRNAs against FOXMl. Expression of FOXMl in response to specific siRNAs (si-FOXMl) or control siRNAs (EGFP, LUC, SCR) in A549 cells, analyzed by semiquantitative RT-PCR (upper panel). Viability of A549 cells, evaluated by triplicate MTT assays, in response to si-FOXMl, EGFP, LUC, or SCR (lower panel).
- (b) depicts inhibition of growth of NSCLC cells by siRNAs against FOXMl .
- FIG. 17 is a schematic model for promotion of cancer cell growth and invasion through the NMU-receptor interaction in the autocrine NMU-GHSRlb oncogenic signaling pathway.
- Binding of NMU to GHSRlb and/or NTSRl leads to the activation of adenylate cyclase, accumulation of intracellular cAMP and following activation of cAMP-dependent protein kinase (PKA).
- PKA cAMP-dependent protein kinase
- C catalytic subunits of PKA
- R regulatory subunits
- genes specifically up-regulated in non-small cell lung cancers were searched by means of cDNA microarray. Through the analysis, a couple of candidate therapeutic target genes were identified. Two genes, KH domain containing protein over-expressed in cancer (KOCl) and neuromedin U (NMU) were abundantly expressed in clinical NSCLC samples as well as NSCLC cell lines examined. However, their expression was hardly detectable in corresponding non-cancerous lung tissue.
- NSCLC cells that over-expressed endogenous NMU was significantly inhibited by anti-NMU antibody. Furthermore, the treatment of NSCLC cells with siRNA against KOCl and/or NMU suppressed the expression of the gene and resulted in growth inhibition ofthe NSCLC cells. Furthermore, KOCl was identified to bind to kinesin family member 11 (KIFl 1) of the cancer cells, whereas NMU bound to the neuropeptide G protein-coupled receptors (GPCRs), growth hormone secretagogue receptor lb (GHSRlb) and neurotensin receptor 1 (NTSRl). NMU ligand-receptor, system was identified to activate Homo sapiens forkhead box Ml (FOXMl).
- GPCRs neuropeptide G protein-coupled receptors
- GHSRlb growth hormone secretagogue receptor lb
- NTSRl neurotensin receptor 1
- GHSRlb, NTSRl , FOXMl , and KIF 11 were all specifically over-expressed in NSCLC cells.
- RNA binding protein KOCl and microtubles motor protein KIFl 1 is required for the localization of some kinds of mRNA needed in embryogenesis and carcinogenesis (Fig. 12).
- siRNA As previously reported by the present inventors, treatment of NSCLC cells with specific siRNA to reduce expression of KOCl resulted in growth suppression.
- KIFll was • demonstrated to associate with KOCl in NSCLC cells and to be the target for the growth-promoting effect of KOCl in lung tumors.
- the present inventors revealed that KOCl not only co-localized with KIFl 1 in human normal tissues, NSCLCs, and cell lines, but also directly interacted with KIFl 1 in NSCLC cells in vitro, and that the treatment of NSCLC cells with siRNAs for KIFl 1 reduced its expression and led to growth suppression.
- the results show that KOC 1 -KIF 11 signaling affects growth of NSCLC cells.
- dominant negative fragments of KOCl e.g., those containing the RRM domains
- increased expression of KOCl and KIFl 1 was detected in the majority of NSCLC samples, but not in normal lung tissues.
- KOCl and KIFl 1 can be conveniently used as a biomarker for diagnosing early-stage lung cancer, in combination with fiberscopic transbronchial biopsy (TBB) of sputum cytology. Therefore, KOCl and KIFl 1 are essential for an oncogenic pathway in NSCLCs.
- TLB fiberscopic transbronchial biopsy
- siRNAs can be used to treat chemotherapy-resistant, advanced lung cancers.
- NMU is an important growth factor for NSCLC and is associated with cancer cell invasion, functioning in an autocrine manner, and that screening molecules targeting the NMU-receptor growth-promoting pathway is a useful therapeutic approach for treating NSCLCs.
- SCC SCC, ADC, LCC, and BAC
- BAC normal lung tissues.
- NMU is a secreted protein and most ofthe clinical NSCLC samples used for the present analysis were at an early and operable stage, NMU can be conveniently used as a biomarker for diagnosis of early-stage lung cancer, in combination with fiberscopic transbronchial biopsy (TBB), sputum cytology, or blood tests.
- TAB fiberscopic transbronchial biopsy
- FM4 Two receptors, NMU1 R (FM3/GPR66) and NMU2R (FM4) are known to interact with NMU.
- GHSR is a known receptor of Ghrelin (GHRL), a recently identified 28-amino-acid peptide capable of stimulating release of pituitary growth hormone and appetite in humans (Lambert, P.D. et al, Proc. Natl. Acad. Sci. 98: 4652-4657 (2001); Petersenn, S. et al, Endocrinology 142: 2649-2659 (2001); Kim K. et al, Clin.
- GHRL Ghrelin
- NTSRl neurotensin
- NTS modulates transmission of dopamine and secretion of pituitary hormones, and exerts hypothermic and analgesic effects in the brain while it functions as a peripheral hormone in the digestive tract and cardiovascular system.
- SCLC small-cell lung cancers
- the expression of NTS was detected in four ofthe 15 NSCLC cell lines that were examined in the present invention (Fig. 13a), but the expression pattern of NTS was not necessarily concordant with that of NMU or NTSRl .
- NTS may, along with NMU, contribute to the growth of NSCLC through NTSRl or other receptor(s) in a small subset of NSCLCs.
- NMU signaling pathway affects the growth promotion of lung-cancer cells by transactivating a set of downstream genes including FOXMl.
- FOXMl was known to be over-expressed in several types of human cancers (Teh, M.T. et al, Cancer Res.
- the "forkhead 1 gene family originally identified in Drosophila, comprises transcription factors with a conserved 100-amino acid DNA-binding motif, and has been shown to play important roles in regulating the expression of genes involved in cell growth, proliferation, differentiation, longevity, and transformation.
- Cotransfection assays in the human hepatoma HepG2 cell line demonstrated that FOXMl protein stimulated expression of both the cyclin Bl (CCNB1) and cyclin Dl (CCND1) (Wang, X.
- NMU two newly revealed receptors for this molecule, GHSRlb and NTSRl, and their downstream gene FOXMl are involved in an autocrine growth-promoting pathway in NSCLCs.
- the data reported here provide the basis for designing new anti-cancer drugs, specific for lung cancer, that target the NMU-GHSRlb/NTSRl -FOXMl pathway. They also show that siRNAs that interfere with this pathway can be used to treat chemotherapy-resistant, advanced lung cancers.
- KOCl -KIF 11 signaling pathway is frequently up-regulated in lung carcinogenesis, and that NMU an important autocrine growth factor for NSCLC, acting through GHSRlb and NTSRl receptor molecules.
- selective suppression of components of these complexes can suppress the development and/or progression of lung carcinogenesis and targeting these pathways are conveniently used in therapeutic and diagnostic strategies for the treatment of lung-cancer patients.
- NSCLC non-small cell lung cancer
- the expression level of a gene can be detected by detecting the expression products ofthe gene, including both transcriptional and translational products, such as mRNA and proteins.
- KIFll NM_004523
- GHSRlb NM_004122
- NTSRl NM_002531
- FOXMl No.NM_202003
- sequences of the KIF 11 , GHSR1 b, NTSRl , and FOXMl genes are described as SEQ ID NOs: 1, 3, 5, and 106, respectively, and the amino acid sequences ofthe proteins encoded by the genes are described as SEQ ID NOs: 2, 4, 6, and 107.
- GHSRlb, NTSRl or FOXMl gene can be used to construct probes for detecting their mRNAs by, e.g., Northern blot hybridization analysis.
- the hybridization ofthe probe to a gene transcript in a subject biological sample can be also carried out on a DNA array.
- the use of an array is preferred for detecting the expression level of a plurality ofthe NSC genes (KIFl 1, GHSRlb, NTSRl, and FOXMl).
- sequences can be used to construct ' primers for specifically amplifying KIFll, GHSRlb, NTSRl or FOXMl gene in, e.g., amplification-based detection methods such as reverse-transcription based polymerase chain reaction (RT-PCR).
- amplification-based detection methods such as reverse-transcription based polymerase chain reaction (RT-PCR).
- the expression level of KIFl 1 , GHSRlb, NTSRl or FOXMl gene can be analyzed based on the quantity ofthe expressed proteins encoded by the gene.
- a method for determining the quantity ofthe expressed protein includes immunoassay methods.
- the expression level of KIFll, GHSRlb, NTSRl or FOXMl gene can also be determined based on the biological activity ofthe expressed protein encoded by the gene.
- a protein encoded by KIFll gene is known to bind to KOCl, and thus the expression level ofthe gene can be detected by measuring the binding ability to KOCl due to the expressed protein.
- KIF 11 protein is known to have a cell proliferating activity. Therefore, the expression level of KIFl 1 gene can be determined using such cell proliferating activity as an index.
- GHSRlb and NTSRl proteins are known to bind to NMU, and also have a cell proliferating activity.
- the expression levels of GHSR1 b and NTSRl genes can be detected by measuring their binding ability to NMU or cell proliferating activity due to the expressed protein.
- any biological materials may be used as the biological sample for determining the expression level so long as any ofthe KIFl 1, GHSRlb, NTSRl, and FOXMl genes can be detected in the sample and includes test cell populations (/. e. , subject derived tissue sample).
- the biological sample comprises a lung cell (a cell obtained from the lung). Gene expression may also be measured in blood, serum or other bodily fluids such as sputum.
- the test sample may be cells purified from a tissue.
- the subject diagnosed for NSCLC according to the method is preferably a mammal and includes human, non-human primate, mouse, rat, dog, cat, horse and cow.
- the expression level of one or more of KIFl 1, GHSRlb, NTSRl or FOXMl gene in the biological sample is compared to the expression level(s) ofthe same genes in a reference sample.
- the reference sample includes one or more cells with known parameters, i.e., cancerous or non-cancerous.
- the reference sample should be derived from a tissue type similar to that of the test sample.
- the control expression level may be determined based on a database of molecular information derived from cells for which the assayed parameter or condition is known. Whether or not a pattern ofthe gene expression levels in a biological sample indicates the presence of NSCLC depends upon the composition ofthe reference cell population.
- test biological sample may be compared to multiple reference samples. Each ofthe multiple reference samples may differ in the known parameter.
- a test sample may be compared to a reference sample known to contain, e.g., NSCLC cells, and at the same time to a second reference sample known to contain, e.g., non-NSCLC cells (normal cells).
- the expression of one or more ofthe NSCLC-associated genes, KIFll, GHSRlb, NTSRl, and FOXMl is determined in the biological sample and compared to the normal control level ofthe same gene.
- normal control level refers to an expression profile of KIFl 1, GHSRlb, NTSRl or FOXMl gene typically found in a biological sample derived from a population not suffering from NSCLC.
- the expression level of KIFl 1 , GHSRlb, NTSRl or FOXMl gene in the biological samples from a control, and test subjects may be determined at the same time or the normal control level may be determined by a statistical method based on the results obtained by analyzing the expression level ofthe gene in samples previously collected from a control group.
- An increase ofthe expression level of KIFll, GHSRlb, NTSRl or FOXMl gene in the biological sample derived from a patient derived tissue sample indicates that the subject is suffering from or is at risk of developing NSCLC.
- An expression level of KIFl 1, GHSRlb, NTSRl or FOXMl gene in a test biological sample can be considered altered when the expression level differs from that ofthe reference by more than 1.0, 1.5, 2.0, 5.0, 10.0 or more fold.
- an expression level of KIFll, GHSRlb, NTSRl or FOXMl gene in a test biological sample can be considered altered, when the expression level is increased or decreased to that ofthe reference at least 50%, 60%, 80%, 90% or more.
- the difference in gene expression between the test sample and a reference sample may be normalized to a control, e.g., housekeeping gene.
- a control polynucleotide includes those whose expression levels are known not to differ between the cancerous and non-cancerous cells.
- the expression levels ofthe control polynucleotide in the test and reference samples can be used to normalize the expression levels detected for KIFll, GHSRlb, NTSRl or FOXMl gene.
- the control genes to be used in the present invention include ⁇ -actin, glyceraldehyde 3 -phosphate dehydrogenase and ribosomal protein PI.
- the differentially expressed KIFl 1, GHSRlb, NTSRl or FOXMl gene identified herein also allow for monitoring the course of treatment of NSCLC.
- a test biological sample is provided from a subject undergoing treatment for NSCLC. If desired, multiple test biological samples are obtained from the subject at various time points before, during or after the treatment.
- the expression of one or more of KIFll, GHSRlb, NTSRl or FOXMl gene in the sample is then determined and compared to a reference sample with a known state of NSCLC that has not been exposed to the treatment. If the reference sample contains no NSCLC cells, a similarity in the expression level of KIFll, GHSRlb, NTSRl or FOXMl gene in the test biological sample and the reference sample indicates the efficaciousness ofthe treatment.
- a difference in the expression level of KIFll, GHSRlb, NTSRl or FOXMl gene in the test and the reference samples indicates a less favorable clinical outcome or prognosis.
- increased expression of KOCl, KIFll, or KOCl in combination with increased expression of KIFll is significantly associated with poor prognosis.
- the term "efficacious" refers that the treatment leads to a reduction in the expression of a pathologically up-regulated gene (including the present indicator genes, KIFll, GHSRlb, NTSRl, and FOXMl), or a decrease in size, prevalence or metastatic potential of NSCLC in a subject.
- efficacious means that the treatment retards or prevents occurrence of NSCLC or alleviates a clinical symptom of NSCLC
- the assessment of NSCLC can be made using standard clinical protocols.
- efficaciousness of a treatment is determined in association with any known method for - diagnosing or treating NSCLC. For example, NSCLC is diagnosed histopathologically or by identifying symptomatic anomalies such as chronic cough, hoarseness, coughing up blood, weight loss, loss of appetite, shortness of breath, wheezing, repeated bouts of bronchitis or • pneumonia and chest pain.
- the present method for diagnosing NSCLC may also be applied for assessing the prognosis of a patient with the cancer by comparing the expression level of KIFl 1, KOCl, GHSRlb, NTSRl, FOXMl gene, or a combination thereof (e.g., KOCl and KIFl 1) in the patient-derived biological sample.
- the expression level ofthe gene(s) in the biological sample may be measured over a spectrum of disease stages to assess the prognosis of the patient.
- An increase in the expression level of KIFl 1, KOCl, GHSRlb, NTSRl or FOXMl gene compared to a normal control level indicates less favorable prognosis.
- a similarity in the expression level of KIFll, KOCl, GHSRlb, NTSRl or FOXMl gene compared to anormal control level indicates a more favorable prognosis of he patient.
- the prognosis of a subject can be assessed by comparing the expression profile of KIFll, KOCl, GHSRlb, NTSRl or FOXMl gene.
- expression levels of KIFl 1 and KOCl are determined.
- Expression profile also provides an NSCLC reference expression profile comprising a pattern of gene expression levels of two or more of KIFl 1, KOCl, GHSRlb, NTSRl and FOXMl genes.
- kits ofthe invention The invention also provides a kit comprising two or more detection reagents, e.g., a nucleic acid that specifically binds to or identifies one or more of KIFll, KOCl, GHSRlb, NTSRl and FOXMl genes.
- nucleic acids specifically binding to or identifying one or more of KIFl 1, KOCl, GHSRlb, NTSRl and FOXMl genes are exemplified by oligonucleotide sequences that are complementary to a portion of KIFll, KOCl, GHSRlb, NTSRl or FOXMl polynucleotides or antibodies which bind to polypeptides encoded by the KIFll, KOCl, GHSRlb, NTSRl or FOXMl gene.
- the reagents are packaged together in the form of a kit.
- the reagents such as a nucleic acid or antibody (either bound to a solid matrix or packaged separately with reagents for binding them to the matrix), a control reagent (positive and/or negative) and/or a means of detection ofthe nucleic acid or antibody are preferably packaged in separate containers. Instructions (e.g., written, tape, VCR, CD-ROM, etc.) for carrying out the assay may be included in the kit.
- the assay format ofthe kit may be Northern hybridization or sandwich ELISA known in the art.
- a detection reagent is immobilized on a solid matrix such as a porous strip to form at least one detection site.
- the measurement or detection region ofthe porous strip may include a plurality of detection sites, each detection site containing a detection reagent.
- a test strip may also contain sites for negative and/or positive controls. Alternatively, control site(s) is located on a separate strip from the test strip.
- the different detection sites may contain different amounts of immobilized reagents, i.e., a higher amount in the first detection site and lesser amounts in subsequent sites.
- the number of sites displaying a detectable signal provides a quantitative indication ofthe amount of KIFl 1, GHSRlb, NTSRl or FOXMl gene, or polypeptides encoded by the gene present in the sample.
- the detection sites may be configured in any suitably detectable shape and are typically in the shape of a bar or dot spanning the width of a teststrip.
- the kit contains a nucleic acid substrate array comprising two or more ofthe KIFll, GHSRlb, NTSRl, and FOXMl gene sequences.
- the expression of 2 or 3 ofthe genes represented by KIFll, GHSRlb, NTSRl, and FOXMl genes are identified by virtue ofthe level of binding to an array test strip or chip.
- the substrate array can be on, e.g., a solid substrate, e.g., a "chip" as described in U.S. Patent No. 5,744,305.
- kits can be used for predicting an NSCLC prognosis.
- the kits in these embodiments can comprise a reagent for detecting mRNA encoding the amino acid sequence of KIFll or KOCl, a reagent for detecting the proteins or reagents for detecting the biological activity ofthe KIFll or KOCl protein.
- the invention also provides kits for the detection of a compound that regulates RNA transporting activity.
- the kits may comprise a cell expressing a KIFl 1 polypeptide, or functional equivalent, a KOCl polypeptide, or functional equivalent, and RNA to be transported, and DCTNl.
- the kits ofthe invention may also be used to screen for compounds for treating or preventing
- kits may comprise a KOCl polypeptide, or functional equivalent, and an RNA that is bound by the KOCl polypeptide or functional equivalent.
- RNA transportable with RNA transporter activity of KOCl -KIF 11 complex can be used as the RNA to be transported.
- Prefer RNA can be selected from transcripts of genes shown in table 2, or fragment thereof.
- An RNA to be transported may also be labeled for detecting RNA transporter activity.
- KOCl and KIFl 1 polypeptide or functional equivalent thereof is expressed as fusion protein with signal generating protein for observation by microscopy or cell imaging systems.
- ECFP, EYFP, and EGFP may be used for signal generating protein.
- Array and pluralities The invention also includes a nucleic acid substrate array comprising one or more ofthe KIFl 1, GHSRlb, NTSRl, and FOXMl genes.
- the nucleic acids on the array specifically correspond to one or more polynucleotide sequences represented by KIFll, GHSRlb, NTSRl, and FOXMl genes.
- the expression level of 2, 3 or 4 ofthe KIFll, GHSRlb, NTSRl, and FOXMl genes is identified by detecting the binding of nucleic acid to the array.
- the invention also includes an isolated plurality (i.e., a mixture of two or more nucleic acids) of nucleic acids.
- the nucleic acids are in a liquid phase or a solid phase, e.g., immobilized on a solid support such as a nitrocellulose membrane.
- the plurality includes one or more ofthe polynucleotides represented by KIF 11 , GHSRl b, NTSRl , and FOXMl genes. According to a further embodiment ofthe present invention, the plurality includes 2, 3, or 4 ofthe polynucleotides represented by KIFll, GHSRlb, NTSRl, and FOXMl genes.
- the DNA chip is a device that is convenient to compare the expression levels of a number of genes at the same time.
- DNA chip-based expression profiling can be carried out, for example, by the method as disclosed in "Microarray Biochip Technology " (Mark Schena, Eaton Publishing, 2000), etc.
- a DNA chip comprises immobilized high-density probes to detect a number of genes.
- the expression levels of many genes can be estimated at the same time by a single-round analysis. Namely, the expression profile of a specimen can be determined with a DNA chip.
- the DNA chip-based method ofthe present invention comprises the following steps of: (1) synthesizing aRNAs or cDNAs corresponding to the marker genes; (2) hybridizing the aRNAs or cDNAs with probes for marker genes; and (3) detecting the aRNA or cDNA hybridizing with the probes and quantifying the amount of mRNA thereof.
- aRNA refers to RNA transcribed from a template cDNA with RNA polymerase.
- An aRNA transcription kit for DNA chip-based expression profiling is commercially available. With such a kit, aRNA can be synthesized from T7 promoter-attached cDNA as a template using T7 RNA polymerase.
- cDNA can be amplified using as a template a cDNA synthesized from mRNA.
- the DNA chip comprises probes, which have been spotted thereon, to detect the marker genes ofthe present invention (KIFl 1, GHSRlb, NTSRl or FOXMl gene).
- the marker genes ofthe present invention KIFl 1, GHSRlb, NTSRl or FOXMl gene.
- the marker genes ofthe present invention KIFl 1, GHSRlb, NTSRl or FOXMl gene.
- the marker genes ofthe present invention KIFl 1, GHSRlb, NTSRl or FOXMl gene.
- Any other genes as well as the marker genes can be spotted on the DNA chip.
- a probe for a gene whose expression level is hardly altered may be spotted on the DNA chip.
- Such a gene can be used to normalize assay results when the assay results are intended to be compared between multiple chips or between different assays.
- a probe is designed for each marker gene selected, and spotted on a DNA chip.
- Such a probe may be, for example, an oligonucleotide comprising 5-50 nucleotide residues.
- a method for synthesizing such oligonucleotides on a DNA chip is known to those skilled in the art.
- Longer DNAs can be synthesized by PCR or chemically.
- a method for spotting long DNA, which is synthesized by PCR or the like, onto a glass slide is also known to those skilled in the art.
- a DNA chip that is obtained by the method as described above can be used for diagnosing NSCLC according to the present invention.
- the prepared DNA chip is contacted with aRNA, followed by the detection of hybridization between the probe and aRNA.
- the aRNA can be previously labeled with a fluorescent dye.
- a fluorescent dye such as Cy3 (red) and Cy5 (green) can be used to label an aRNA.
- aRNAs from a subject and a control are labeled with different fluorescent dyes, respectively.
- the difference in the expression level between the two can be estimated based on a difference in the signal intensity.
- the signal of fluorescent dye on the DNA chip can be detected by a scanner and analyzed using a special program.
- the Suite from Affymetrix is a software package for DNA chip analysis.
- Identifying compounds that inhibit NSCLC-associated gene expression A compound that inhibits the expression or activity of a target NSCLC-associated gene (KIFll, GHSRlb, NTSRl or FOXMl gene) is identified by contacting a test cell expressing the NSCLC-associated gene with a test compound and determining the expression level or activity ofthe NSCLC-associated gene. A decrease in expression compared to the normal control level indicates that the compound is an inhibitor ofthe NSCLC-associated gene.
- Such compounds identified according to the method are useful for inhibiting NSCLC
- the test cell may be a population of cells and includes any cells as long as the cell expresses the target NSCLC-associated gene(s).
- the test cell may be an immortalized cell line derived from an NSCLC cell.
- test cell may be a cell transfected with any ofthe KIFl 1, GHSRlb, NTSRl, and FOXMl genes, or which has been transfected with the regulatory sequence (e.g., promoter) of any ofthe genes that is operably linked to a reporter gene.
- regulatory sequence e.g., promoter
- the present invention provides a method of screening for a compound for treating or preventing NSCLC using the polypeptide of the present invention.
- An embodiment of this screening method comprises the steps of: (a) contacting a test compound with a polypeptide encoded by KIFll, GHSRlb, NTSRl or FOXMl gene; " (b) detecting the binding activity between the polypeptide ofthe present invention and the test compound; and (c) selecting the compound that binds to the polypeptide.
- KOCl and KIFll form a complex that has RNA transporting activity.
- the present invention also provides methods of identifying polypeptides and other compounds that modulate RNA transport activity.
- a polypeptide can be tested for RNA transporting activity by contacting a KIFl 1 polypeptide (SEQ ID NO: 2) or a functional equivalent thereof with an RNA that can be transported by KIFl 1 under conditions suitable for transportation of RNA.
- the level of RNA transported can be measured using well known techniques, such as by RNA immunoprecipitation, as described in detail below.
- a functional equivalent of a KIFl 1 polypeptide is a polypeptide that has a biological activity equivalent to a polypeptide consisting ofthe amino acid sequence of SEQ ID NO: 2 and, for example, comprising the amino acid sequence of SEQ ID NO: 2 (KIFll), wherein one or more amino acids (usually less than five) are substituted, deleted, or inserted.
- the polypeptide may be one that comprises an amino acid sequence having at least about 80% homology (also referred to as sequence idenitity) to SEQ ID NO: 2.
- the polypeptide can be encoded by a polynucleotide that hybridizes under stringent conditions (as defined below) to a polynucleotide consisting ofthe nucleotide sequence of SEQ ID NO: 1.
- the KIFl 1 polypeptide or functional equivalent is contacted with a
- KOC 1 polypeptide or functional equivalent thereof A functional equivalent of a KOC 1 polypeptide is a polypeptide that has a biological activity equivalent to a polypeptide consisting ofthe amino acid sequence of SEQ ID NO: 105 and, for example, comprising the amino acid sequence of SEQ ID NO: 105, wherein one or more amino acids (usually less than five) are substituted, deleted, or inserted.
- the polypeptide may be one that comprises an amino acid sequence having at least about 80% homology (also referred to as sequence idenitity) to SEQ ID NO: 105.
- the polypeptide can be encoded by a polynucleotide that hybridizes under stringent conditions (as defined below) to a polynucleotide consisting ofthe nucleotide sequence of SEQ ID NO: 104.
- a functional equivalent comprises at least one RRM or KH domain.
- the invention also provides methods of identifying agents that modulate RNA transporting activity. In these methods, an agent suspected of modulating RNA transporting activity with a KIFl 1 polypeptide or functional equivalent. The level of transported RNA is detected and ' compared to the level in a control in the absence ofthe agent.
- the polypeptide to be used for the screening may be a recombinant polypeptide or a protein derived from the nature or a partial peptide thereof.
- the polypeptide to be contacted with a test compound can be, for example, a purified polypeptide, a soluble protein, a form bound to a carrier or a fusion protein fused with other polypeptides.
- a method of screening for proteins that bind to KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide many methods well known by a person skilled in the art can be used. Such a screening can be conducted by, for example, immunoprecipitation method using methods well known in the art.
- the proteins ofthe invention can be recombinantly produced using standard procedures.
- a gene encoding any ofthe KIFll, GHSRlb, NTSRl, and FOXMl polypeptides is expressed in animal cells by inserting the gene into an expression vector for foreign genes, such as pSN2neo, pcD ⁇ A I, pcD ⁇ A3.1 , pCAGGS and pCD8.
- the promoter to be used for the expression may be any promoter that can be used commonly and include, for example, the SV40 early promoter (Rigby in Williamson (ed.), Genetic Engineering, vol. 3.
- the introduction ofthe gene into animal cells to express a foreign gene can be performed according to any methods, for example, the electroporation method (Chu et al, Nucleic Acids Res 15: 1311 -26 (1987)), the calcium phosphate method (Chen and Okayama, Mol Cell Biol 1: 2745-52 (1987)), the DEAE dextran method (Lopata et al, Nucleic Acids Res 12: 5707-17 (1984); Sussman and Milman, Mol Cell Biol 4: 1642-3 (1985)), the Lipofectin method (Derijard, B Cell 1: 1025-37 (1994); Lamb et al, Nature Genetics 5: 22-30 (1993): Rabindran et al, Science 259: 230-4 (1993)), and so on.
- electroporation method Chou et al, Nucleic Acids Res 15: 1311 -26 (1987)
- the calcium phosphate method Choen and Okayama, Mol Cell Biol 1: 2745-52
- the NSC polypeptide can also be expressed as a fusion protein comprising a recognition site (epitope) of a monoclonal antibody by introducing the epitope ofthe monoclonal antibody, whose specificity has been revealed, to the N- or C- terminus ofthe polypeptide.
- a commercially available epitope-antibody system can be used (Experimental Medicine 13: 85-90 (1995)).
- Vectors which can express a fusion protein with, for example, ⁇ -galactosidase, maltose binding protein, glutathione S-transferase, green florescence protein (GFP), and so on, by the use of its multiple cloning sites are commercially available.
- a fusion protein prepared by introducing only small epitopes consisting of several to a dozen amino acids so as not to change the property ofthe original polypeptide by the fusion is also reported.
- Epitopes such as polyhistidine (His-tag), influenza aggregate HA, human c-myc, FLAG, Vesicular stomatitis virus glycoprotein (VSV-GP), T7 gene 10 protein (T7-tag), human simple herpes virus glycoprotein (HSV-tag), E-tag (an epitope on monoclonal phage) and such, and monoclonal antibodies recognizing them can be used as the epitope-antibody system for screening proteins binding to the KIFll, GHSRlb, NTSRl or FOXMl polypeptide (Experimental Medicine 13: 85-90 (1995)).
- an immune complex is formed by adding these antibodies to cell lysate prepared using an appropriate detergent.
- the immune complex consists ofthe KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide, a polypeptide comprising the binding ability with the polypeptide, and an antibody.
- Immunoprecipitation can be also conducted using antibodies against the KIFll, GHSRlb, NTSRl or FOXMl polypeptide, in addition to the use of antibodies against the above epitopes, which antibodies can be prepared according to conventional methods and may be in any form, such as monoclonal or polyclonal antibodies, and includes antiserum obtained by immunizing an animal such as a rabbit with the polypeptide, all classes of polyclonal and monoclonal antibodies, as well as recombinant antibodies (e.g., humanized antibodies). Specifically, antibodies against KIFll, GHSRlb, NTSRl or FOXMl polypeptide can be prepared using techniques well known in the art.
- KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide used as an antigen to obtain an antibody may be derived from any animal species, but preferably is derived from a mammal such as a human, mouse, or rat, more preferably from a human.
- the polypeptide used as the antigen can be recombinantly produced or isolated from natural sources.
- the polypeptide to be used as an immunization antigen may be a complete protein or a partial peptide ofthe KIFll, GHSRlb, NTSRl or FOXMl polypeptide.
- a partial peptide may comprise, for example, the amino (N)-terminal or carboxy (C)-terminal fragment ofthe KIFll, GHSRlb, NTSRl or FOXMl polypeptide.
- Any mammalian animal may be immunized with the antigen, but preferably the compatibility with parental cells used for cell fusion is taken into account.
- animals of Rodentia, Lagomorpha or Primates are used.
- Animals of Rodentia include, for example, mouse, rat and hamster.
- Animals of Lagomorpha include, for example, rabbit.
- Animals of Primates include, for example, a monkey of Catarrhini (old world monkey) such as Macacafascicularis, rhesus monkey, sacred baboon and chimpanzees.
- Methods for immunizing animals with antigens are known in the art. Intraperitoneal injection or subcutaneous injection of antigens is a standard method for immunization of mammals. More specifically, antigens may be diluted and suspended in an appropriate amount of phosphate buffered saline (PBS), physiological saline, etc. If desired, the antigen suspension may be mixed with an appropriate amount of a standard adjuvant, such as Freund's complete adjuvant, made into emulsion, and then administered to mammalian animals.
- PBS phosphate buffered saline
- the antigen suspension may be mixed with an appropriate amount of a standard adjuvant, such as Freund's complete adjuvant, made into emulsion, and then administered to mammalian animals.
- the serum is examined by a standard method for an increase in the amount of desired antibodies.
- Polyclonal antibodies against KIFll, GHSRlb, NTSRl or FOXMl polypeptide may be prepared by collecting blood from the immunized mammal examined for the increase of desired antibodies in the serum, and by separating serum from the blood by any conventional method.
- Polyclonal antibodies include serum containing the polyclonal antibodies, as well as the fraction containing the polyclonal antibodies may be isolated from the serum.
- Immunoglobulin G or M can be prepared from a fraction which recognizes only the KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide using, for example, an affinity column coupled with the polypeptide, and further purifying this fraction using protein A or protein G column.
- To prepare monoclonal antibodies immune cells are collected from the mammal immunized with the antigen and checked for the increased level of desired antibodies in the serum as described above, and are subjected to cell fusion.
- the immune cells used for cell fusion are preferably obtained from spleen.
- Other preferred parental cells to be fused with the above immunocyte include, for example, myeloma cells of mammalians, and more preferably myeloma cells having an acquired property for the selection of fused cells by drugs.
- the above immunocyte and myeloma cells can be fused according to known methods, for example, the method of Milstein et al, (Galfre and Milstein, Methods Enzymol 73 : 3-46 (1981)).
- Resulting hybridomas obtained by the cell fusion may be selected by cultivating them in a standard selection medium, such as HAT medium (hypoxanthine, aminopterin, and thymidine containing medium).
- the cell culture is typically continued in the HAT medium for several days to several weeks, the time being sufficient to allow all the other cells, with the exception of the desired hybridoma (non-fused cells), to die. Then, the standard limiting dilution is performed to screen and clone a hybridoma cell producing the desired antibody.
- human lymphocytes such as those infected by EB virus may be immunized with KIFl 1 , GHSRlb, NTSRl or FOXMl polypeptide, cells expressing the polypeptide, or their lysates in vitro.
- the immunized lymphocytes are fused with human-derived myeloma cells that are capable of indefinitely dividing, such as U266, to yield a hybridoma producing a desired human antibody that is able to bind to the KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide can be obtained (Unexamined Published Japanese Patent Application No. (JP-A) Sho 63-17688).
- the obtained hybridomas are subsequently transplanted into the abdominal cavity of a mouse and the ascites are extracted.
- the obtained monoclonal antibodies can be purified by, for example, ammonium sulfate precipitation, a protein A or protein G column, DEAE ion exchange chromatography, or an affinity column to which any ofthe target proteins ofthe present invention (KIFll, GHSRlb, NTSRl, and FOXMl polypeptide) is coupled.
- the antibody can be used not only in the present screening method, but also for purification and detection of KIFll, GHSRlb, NTSRl or FOXMl polypeptide, and serve also as candidates for agonists and antagonists ofthe polypeptide.
- this antibody can be applied to the antibody treatment for diseases related to the KIFll, GHSRlb, NTSRl or FOXMl polypeptide including NSCLC as described infra.
- Monoclonal antibodies thus obtained can be also recombinantly prepared using genetic engineering techniques (see, for example, Borrebaeck and Larrick, Therapeutic Monoclonal Antibodies, published in the United Kingdom by MacMillan Publishers LTD (1990)).
- a DNA encoding an antibody may be cloned from an immune cell, such as a hybridoma or an immunized lymphocyte producing the antibody, inserted into an appropriate vector, and introduced into host cells to prepare a recombinant antibody.
- an antibody used in the screening and so on may be a fragment of an antibody or modified antibody, so long as it binds to one or more of KIFll, GHSRlb, NTSRl, and FOXMl polypeptides.
- the antibody fragment may be Fab, F(ab') 2 , Fv, or single chain Fv (scFv), in which Fv fragments from H and L chains are ligated by an appropriate linker (Huston et al, Proc Natl Acad Sci USA 85: 5879-83 (1988)). More specifically, an antibody fragment may be generated by treating an antibody with an enzyme, such as papain or pepsin.
- a gene encoding the antibody fragment may be constructed, inserted into an expression vector, and expressed in an appropriate host cell (see, for example, Co et al, J Immunol 152: 2968-76 (1994); Better and Horwitz, Methods Enzymol 178: 476-96 (1989); Pluckthun and Skerra, Methods Enzymol 178: 497-515 (1989); Lamoyi, Methods Enzymol 121: 652-63 (1986); Rousseaux et al, Methods Enzymol 121 : 663-9 (1986); Bird and Walker, Trends Biotechnol 9: 132-7 (1991)).
- An antibody may be modified by conjugation with a variety of molecules, such as polyethylene glycol (PEG).
- Modified antibodies can be obtained through chemically modification of an antibody. These modification methods are conventional in the field.
- an antibody may be obtained as a chimeric antibody, between a variable region derived from nonhuman antibody and the constant region derived from human antibody, or as a humanized antibody, comprising the complementarity determining region (CDR) derived from nonhuman antibody, the frame work region (FR) derived from human antibody, and the constant region.
- CDR complementarity determining region
- FR frame work region
- Humanization can be performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody (see e.g., Verhoeyen et al, Science 239:1534-1536 (1988)). Accordingly, such humanized antibodies are chimeric antibodies, wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
- Fully human antibodies comprising human variable regions in addition to human framework and constant regions can also be used.
- Such antibodies can be produced using various techniques known in the art. For example in vitro methods involve use of recombinant libraries of human antibody fragments displayed on bacteriophage (e.g., Hoogenboom & Winter, J. Mol. Biol. 227:381 (1991), Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. This approach is described, e.g., in U.S. Patent Nos.
- Antibodies obtained as above may be purified to homogeneity.
- the separation and purification ofthe antibody can be performed according to separation and purification methods used for general proteins.
- the antibody may be separated and isolated by the appropriately selected and combined use of column chromatographies, such as affinity chromatography, filter, ultrafiltration, salting-out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing, and others (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory (1988)), but are not limited thereto.
- a protein A column and protein G column can be used as the affinity column.
- Exemplary protein A columns to be used include, for example, Hyper D, POROS, and Sepharose F.F. (Pharmacia).
- Exemplary chromatography, with the exception of affinity includes, for example, ion-exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, adsorption chromatography, and the like (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al, Cold Spring Harbor Laboratory Press (1996)).
- the chromatographic procedures can be carried out by liquid-phase chromatography, such as HPLC and FPLC.
- An immune complex can be precipitated, for example with Protein A sepharose or Protein G sepharose when the antibody is a mouse IgG antibody.
- the KIFll, GHSRlb, NTSRl or FOXMl polypeptide is prepared as a fusion protein with an epitope, such as GST, an immune complex can be formed in the same manner as in the use ofthe antibody against the KIFll, GHSRlb, NTSRl or FOXMl polypeptide, using a substance specifically binding to these epitopes, such as glutathione-Sepharose 4B.
- Immunoprecipitation can be performed by following or according to, for example, the methods in the literature (Harlow and Lane, Antibodies, 511-52, Cold Spring Harbor Laboratory publications, New York (1988)). SDS-PAGE is commonly used for analysis of immunoprecipitated proteins and the bound protein can be analyzed by the molecular weight ofthe protein using gels with an appropriate concentration.
- the detection sensitivity for the protein can be improved by culturing cells in culture medium containing radioactive isotope, S-methionine or S-cystein, labeling proteins in the cells, and detecting the proteins.
- the target protein can be purified directly from the SDS-polyacrylamide gel and its sequence can be determined, when the molecular weight ofthe protein has been revealed.
- a protein binding to KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide can be obtained by preparing a cDNA library from cells, tissues, organs (for example, tissues such as lung cells) or cultured cells (particularly those derived from NSCLC cells) expected to express a protein binding to the KIFl 1 , GHSRlb, NTSRl or
- FOXMl polypeptide using a phage vector (e.g., ZAP), expressing the protein on LB-agarose, fixing the protein expressed on a filter, reacting the purified and labeled KIFll, GHSRlb, NTSRl or FOXMl polypeptide with the above filter, and detecting the plaques expressing proteins bound to the KIFll, GHSRlb, NTSRl or FOXMl polypeptide according to the label.
- a phage vector e.g., ZAP
- the KIFll, GHSRlb, NTSRl or FOXMl polypeptide may be labeled by utilizing the binding between biotin and avidin, or by utilizing an antibody that specifically binds to the KIFll, GHSRlb, NTSRl or FOXMl polypeptide, or a peptide or polypeptide (for example, GST) that is fused to the KIFll, GHSRlb, NTSRl or FOXMl polypeptide. Methods using radioisotope or fluorescence and such may be also used.
- a two-hybrid system utilizing cells may be used ("MATCHMAKER Two-Hybrid system", “Mammalian MATCHMAKER Two-Hybrid Assay Kit”, “MATCHMAKER one-Hybrid system” (Clontech); “HybriZAP Two-Hybrid Vector System” (Stratagene); the references “Dalton and Treisman, Cell 68: 597-612 (1992)", “Fields and Sternglanz, Trends Genet 10: 286-92 (1994)”).
- KIFll, GHSRlb, NTSRl or FOXMl polypeptide is fused to the SRF-binding region or GAL4-binding region and expressed in yeast cells.
- a cDNA library is prepared from cells expected to express a protein binding to the KIFll, GHSRlb, NTSRl or FOXMl polypeptide, such that the library, when expressed, is fused to the VP16 or GAL4 transcriptional activation region.
- the cDNA library is then introduced into the above yeast cells and the cDNA derived from the library is isolated from the positive clones detected (when a protein binding to the polypeptide ofthe invention is expressed in yeast cells, the binding of the two activates a reporter gene, making positive clones detectable).
- a protein encoded by the cDNA can be prepared by introducing the cDNA isolated above to E. coli and expressing the protein.
- a reporter gene for example, Ade2 gene, lacZ gene, CAT gene, luciferase gene and such can be used in addition to the HIS3 gene.
- a compound binding to KIFll, GHSRlb, NTSRl or FOXMl polypeptide can also be screened using affinity chromatography.
- KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide may be immobilized on a carrier of an affinity column, and a test compound, containing a protein capable of binding to KIFll, GHSRlb, NTSRl or FOXMl polypeptide, is applied to the column.
- a test compound herein may be, for example, cell extracts, cell lysates, etc. After loading the test compound, the column is washed, and compounds bound to KIFl 1 , GHSRlb, NTSRl or FOXMl polypeptide can be prepared.
- test compound When the test compound is a protein, the amino acid sequence ofthe obtained protein is analyzed, an oligo DNA is synthesized based on the sequence, and cDNA libraries are screened using the oligo DNA as a probe to obtain a DNA encoding the protein.
- a biosensor using the surface plasmon resonance phenomenon may be used as a mean for detecting or quantifying the bound compound in the present invention. When such a biosensor is used, the interaction between KIFll, GHSRlb, NTSRl or FOXMl polypeptide and a test compound can be observed real-time as a surface plasmon resonance signal, using only a minute amount of polypeptide and without labeling (for example, BIAcore, Pharmacia).
- the present invention provides a method of screening for a compound for treating or preventing NSCLC using KIFll, GHSRlb, NTSRl or FOXMl polypeptide comprising the steps as follows: (a) contacting a test compound with KIFll, GHSRlb, NTSRl or FOXMl polypeptide; (b) detecting the biological activity ofthe KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide of step (a); and (c) selecting a compound that suppresses the biological activity ofthe KIFll, GHSRlb, NTSRl or FOXMl polypeptide in comparison with the biological activity detected in the absence ofthe test compound.
- proteins encoded by any ofthe genes of KIFll, GHSRlb, NTSRl, and FOXMl have the activity of promoting cell proliferation of NSCLC cells, a compound which inhibits this activity of one of these proteins can be screened using this activity as an index.
- Any polypeptides can be used for screening so long as they comprise the biological activity of KIFl 1, GHSRlb, NTSRl or FOXMl proteins.
- Such biological activity includes cell-proliferating activity and binding ability to other proteins ofthe proteins encoded by KIFll, GHSRlb, NTSRl or FOXMl gene.
- a human protein encoded by KIF 11 , GHSRlb, NTSRl or FOXMl gene can be used and polypeptides functionally equivalent to these proteins can also be used. Such polypeptides may be expressed endogenously or exogenously by cells.
- the compound isolated by this screening is a candidate for antagonists ofthe KIFll, GHSRlb, NTSRl or FOXMl polypeptide.
- antagonist refers to molecules that inhibit the function of KIFll, GHSRlb, NTSRl or FOXMl polypeptide by binding thereto.
- a compound isolated by this screening is a candidate for compounds which inhibit the in vivo interaction of KIFll, GHSRlb, NTSRl or FOXMl polypeptide with molecules (including DNAs and proteins).
- the biological activity to be detected in the present method is cell proliferation, it can be detected, for example, by preparing cells which express KIFll, GHSRlb, NTSRl or FOXMl polypeptide, culturing the cells in the presence of a test compound, and determining the speed of cell proliferation, measuring the cell cycle and such, as well as by measuring the colony forming activity.
- KIFll As discussed in detail above, by controlling the expression levels of KIFll, GHSRlb, NTSRl or FOXMl gene, one can control the onset and progression of NSCLC.
- compounds that may be used in the treatment or prevention of NSCLC can be identified through screenings that use the expression levels of one or more of KIFl 1 , GHSRlb, NTSRl , and FOXMl genes as indices.
- such screening may comprise, for example, the following steps: (a) contacting a test compound with a cell expressing one or more of KIFll, GHSRlb, NTSRl, and FOXMl genes; and (b) selecting a compound that reduces the expression level of one or more of he genes in comparison with the expression level detected in the absence ofthe test compound.
- Cells expressing at least one of KIFll, GHSRlb, NTSRl, and FOXMl genes include, for example, cell lines established from NSCLC cells; such cells can be used for the above screening ofthe present invention (e.g., A549, NCI-H226, NCI-H522, LC319).
- the expression level can be estimated by methods well known to one skilled in the art.
- a compound that reduces the expression level of at least one ofthe genes can be selected as candidate agents to be used for the treatment or prevention of NSCLC.
- the screening method ofthe present invention may comprise the following steps: (a) contacting a test compound with a cell into which a vector comprising the transcriptional regulatory region of one or more ofthe marker genes and a reporter gene that is expressed under the control ofthe transcriptional regulatory region has been introduced, wherein the marker genes are selected from the group of KIFll, GHSRlb, NTSRl, and FOXMl; (b) measuring the activity of said reporter gene; and (c) selecting a compound that reduces the expression level of said reporter gene as compared to a control.
- Suitable reporter genes and host cells are well known in the art.
- the reporter construct required for the screening can be prepared using the transcriptional regulatory region of a marker gene.
- a reporter construct can be prepared using the previous sequence information.
- a nucleotide segment containing the transcriptional regulatory region can be isolated from a genome library based on the nucleotide sequence information ofthe marker gene (e.g., based the 5' upstream sequence information).
- the method utilizes the binding ability of KIFll to KOCl, or GHSRlb or NTSRl to NMU.
- KOCl not only co-localized with KIFll in human normal tissues, NSCLCs, and cell lines, but also directly interacted with KIFll in NSCLC cells in vitro, and that the treatment of NSCLC cells with siRNAs for KIFl 1 reduced its expression and led to growth suppression.
- siRNAs for KIFl 1 reduced its expression and led to growth suppression.
- the results suggest that KOCl -KIFl 1 signaling affects growth of NSCLC cells.
- This screening method includes the steps of: (a) contacting a KIFll polypeptide or functional equivalent thereof with KOCl, or a functional equivalent thereof, in the presence of a test compound; (b) detecting the binding between the polypeptide and KOCl ; and (c) selecting the test compound that inhibits the binding between the polypeptide and KOCl. Furthermore, as described above, the present inventors revealed GHSRlb and NTSRl as the likely targets for the growth-promoting effect of NMU in lung tumors.
- the present inventors revealed that NMU-25 bound to these receptors on the cell surface, and that treatment of NSCLC cells with siRNAs for GHSRl or NTSRl reduced expression ofthe receptors and led to apoptosis.
- the results suggest that NMU affects growth of NSCLC cells by acting through GHSRlb and/or NTSRl (Fig. 14).
- GHSRlb or NTSRl a compound that inhibits the binding serve as pharmaceuticals for treating or preventing NSCLCs.
- This screening method includes the steps of: (a) contacting a GHSRlb or NTSRl polypeptide or functional equivalent thereof with NMU in the presence of a test compound; (b) detecting binding between the polypeptide and NMU; and (c) selecting the test compound that inhibits binding between the polypeptide and NMU.
- KOCl and KIFl 1 polypeptides, or GHSRlb or NTSRl and NMU polypeptides to be used for the screening may be a recombinant polypeptide or a protein derived from the nature, or may also be a partial peptide thereof so long as it retains the binding ability to each other. Such partial peptides retaining the binding ability are herein referred to as "functional equivalents".
- the KOCl and KIFll polypeptides, or GHSRlb or NTSRl and NMU polypeptides to be used in the screening can be, for example, a purified polypeptide, a soluble protein, a form bound to a carrier or a fusion protein fused with other polypeptides.
- a method of screening for compounds that inhibit binding between KOCl and KIFll, or GHSRlb or NTSRl and NMU many methods well known by one skilled in the art can be used. Such a screening can be carried out as an in vitro assay system, for example, in a cellular system.
- KOCl or KIFll, or GHSRlb or NTSRl, or NMU is bound to a support, and the other protein is added together with a test compound thereto.
- the mixture is incubated, washed and the other protein bound to the support is detected and/or measured.
- supports that may be used for binding proteins include insoluble polysaccharides, such as agarose, cellulose and dextran; and synthetic resins, such as polyacrylamide, polystyrene and silicon; preferably commercial available beads and plates (e.g., multi-well plates, biosensor chip, etc.) prepared from the above materials may be used. When using beads, they may be filled into a column.
- the use of magnetic beads of also known in the art and enables to readily isolate proteins bound on the beads via magnetism.
- the binding of a protein to a support may be conducted according to routine methods, such as chemical bonding and physical adsorption.
- a protein may be bound to a support via antibodies specifically recognizing the protein.
- binding of a protein to a support can be also conducted by means of avidin and biotin.
- the binding between proteins is carried out in buffer, for example, but are not limited to, phosphate buffer and Tris buffer, as long as the buffer does not inhibit binding between the proteins.
- a biosensor using the surface plasmon resonance phenomenon may be used as a mean for detecting or quantifying the bound protein.
- the interaction between the proteins can be observed real-time as a surface plasmon resonance signal, using only a minute amount of polypeptide and without labeling (for example, BIAcore, Pharmacia). Therefore, it is possible to evaluate binding between the KOCl and KIFl 1, or GHSRlb or NTSRl and NMU using a biosensor such as BIAcore.
- a biosensor such as BIAcore.
- either KOCl or KIFl 1, or GHSRlb or NTSRl, or NMU may be labeled, and the label ofthe bound protein may be used to detect or measure the bound protein.
- the labeled protein is contacted with the other protein in the presence of a test compound, and then bound proteins are detected or measured according to the label after washing.
- Labeling substances such as radioisotope (e.g., 3 H, 14 C, 32 P, 33 P, 35 S, 125 1, 131 I), enzymes (e.g., alkaline phosphatase, horseradish peroxidase, ⁇ -galactosidase, ⁇ -glucosidase), fluorescent substances (e.g., fluorescein isothiosyanete (FITC), rhodamine) and biotin/avidin, may be used for the labeling of a protein in the present method.
- FITC fluorescein isothiosyanete
- biotin/avidin biotin/avidin
- proteins labeled with enzymes can be detected or measured by adding a substrate ofthe enzyme to detect the enzymatic change ofthe substrate, such as generation of color, with absorptiometer. Further, in case where a fluorescent substance is used as the label, the bound protein may be detected or measured using fluorophotometer. Furthermore, binding of KOCl and KIFl 1, or GHSRlb or NTSRl and NMU can be also detected or measured using antibodies to the KOCl and KIFll, or GHSRlb or NTSRl and NMU.
- KOCl polypeptide immobilized on a support with a test compound and KIFll After contacting the KOCl polypeptide immobilized on a support with a test compound and KIFll, the mixture is incubated and washed, and detection or measurement can be conducted using an antibody against KIF 11.
- KIF 11 may be immobilized on a support, and an antibody against KOCl may be used as the antibody.
- GHSRlb or NTSRl polypeptide may be immobilized on a support with a test compound and NMU, the mixture is incubated and washed, and detection or measurement can be conducted using ah antibody against NMU.
- NMU may be immobilized on a support, and an antibody against GHSRlb or NTSRl may be used as the antibody.
- the antibody is preferably labeled with one ofthe labeling substances mentioned above, and detected or measured based on the labeling substance.
- the antibody against KOCl or KIFl 1, or GHSRlb or NTSRl, or NMU may be used as a primary antibody to be detected with a secondary antibody that is labeled with a labeling substance.
- the antibody bound to the protein in the screening ofthe present invention may be detected or measured using protein G or protein A column.
- a two-hybrid system utilizing cells may be used ("MATCHMAKER Two-Hybrid system", “Mammalian MATCHMAKER Two-Hybrid Assay Kit”, “MATCHMAKER one-Hybrid system” (Clontech); “HybriZAP Two-Hybrid Vector System” (Stratagene); the references “Dalton and Treisman, Cell 68: 597-612 (1992)", “Fields and Sternglanz, Trends Genet 10: 286-92 (1994)”).
- KOCl polypeptide is fused to the SRF-binding region or GAL4-binding region and expressed in yeast cells.
- KIFl 1 polypeptide that binds to KOCl polypeptide is fused to the VP16 or GAL4 transcriptional activation region and also expressed in the yeast cells in the existence of a test compound.
- KIFl 1 polypeptide may be fused to the SRF-binding region or GAL4-binding region, and KOCl polypeptide to the VP 16 or GAL4 transcriptional activation region.
- GHSRlb or NTSRl polypeptide is fused to the SRF-binding region or GAL4-binding region and expressed in yeast cells.
- NMU polypeptide that binds to GHSRlb or NTSRl polypeptide is fused to the VP16 or GAL4 transcriptional activation region and also expressed in the yeast cells in the existence of a test compound.
- NMU polypeptide may be fused to the SRF-binding region or GAL4-binding region, and GHSRlb or NTSRl polypeptide to the VP16 or GAL4 transcriptional activation region.
- a reporter gene for example, Ade2 gene, lacZ gene, CAT gene, luciferase gene and such can be used besides HIS3 gene.
- the polypeptides are expressed on the surface of a living cell.
- the binding between the polypeptide and NMU can be detected by methods detecting the autocrine and paracrine signaling leading to stimulation of tumor cell growth (Heasley, Oncogene 20: 1563-1569 (2001)).
- the binding between GHSRl or NTSRl polypeptide and NMU can be detected by: (1) detecting the concentration of calcium or cAMP in the cell (e.g. FLIPR assay, Biochem. Biophys. Res. Commun. 276: 435-438, 2000; Nature 406: 70-74, 2000; J. Biol. Chem. 275:21068-21074, 2000);
- test compound for example, cell extracts, cell culture supernatant, products of fermenting microorganism, extracts from marine organism, plant extracts, purified or crude proteins, peptides, non-peptide compounds, synthetic micromolecular compounds and natural compounds can be used in the screening methods ofthe present invention.
- the test compound ofthe present invention can be also obtained using any ofthe numerous approaches in combinatorial library methods known in the art, including (1) biological libraries, (2) spatially addressable parallel solid phase or solution phase libraries, (3) synthetic library methods requiring deconvolution, (4) the "one-bead one-compound” library method and (5) synthetic library methods using affinity chromatography selection.
- test compound exposed to a cell or protein according to the screening methods ofthe present invention may be a single compound or a combination of compounds. When a combination of compounds are used in the screening methods ofthe invention, the compounds may be contacted sequentially or simultaneously.
- a compound isolated by the screening methods ofthe present invention is a candidate for drugs which inhibit the activity of KIFll, GHSRlb, NTSRl or FOXMl polypeptide, for treating or preventing diseases attributed to, for example, cell proliferative diseases, such as NSCLC.
- a compound effective in suppressing the expression of over-expressed genes, i.e., KIFll, GHSRlb, NTSRl or FOXMl gene is deemed to have a clinical benefit and can be further tested for its ability to prevent cancer cell growth in animal models or test subjects.
- a therapeutic agent for treating and/or preventing NSCLC that is appropriate for a particular individual Differences in the genetic makeup of individuals can result in differences in their relative abilities to metabolize various drugs.
- a compound that is metabolized in a subject to act as an anti-NSCLC agent can manifest itself by inducing a change in gene expression pattern in the subject's cells from that characteristic of a cancerous state to a gene expression pattern characteristic of a non-cancerous state.
- the differentially expressed KIF 11 , GHSRlb, NTSRl, and FOXMl genes disclosed herein allow for selection of a putative therapeutic or prophylactic inhibitor of NSCLC specifically adequate for a subject by testing candidate compounds in a test cell (or test cell population) derived from the selected subject.
- test cell or test cell population derived from the subject is exposed to a therapeutic agent and the expression of one or more ofthe KIFll, GHSRlb, NTSRl, and FOXMl genes is determined.
- the test cell is or the test cell population contains an NSCLC cell expressing an NSCLC-associated gene.
- the test cell is or the test cell population contains a lung cell.
- the test cell or test cell population is incubated in the presence of a candidate agent and the pattern of gene expression ofthe test cell or cell population is measured and compared to one or more reference profiles, e.g., an NSCLC reference expression profile or an non-NSCLC reference expression profile.
- a decrease in the expression of one or more of KIFl 1, GHSRlb, NTSRl, and FOXMl in a test cell or test cell population relative to a reference cell population containing NSCLC is indicative that the agent is therapeutic.
- the test agent can be any compound or composition.
- the test agent is an immunomodulatory agent.
- Methods for treating or preventing NSCLC The present invention provides a method for treating, alleviating or preventing NSCLC in a subject. Therapeutic compounds are administered prophylactically or therapeutically to subjects suffering from or at risk of (or susceptible to) developing NSCLC. Such subjects are identified using standard clinical methods or by detecting an aberrant level of expression or activity of KIFll, GHSRlb, NTSRl or FOXMl gene or polypeptide.
- Prophylactic administration occurs prior to the manifestation of overt clinical symptoms of disease, such that a disease or disorder is prevented or alternatively delayed in its progression.
- the method includes decreasing the expression or function, or both, of one or more gene products of genes whose expression is aberrantly increased ("over-expressed gene"; KIFll, GHSRlb, NTSRl or FOXMl gene) in an NSCLC cell relative to normal cells ofthe same tissue type from which the NSCLC cells are derived.
- the expression may be inhibited by any method known in the art. For example, a subject may be treated with an effective amount of a compound that decreases the amount of one or more ofthe KIFl 1, GHSRlb, NTSRl or FOXMl gene in the subject.
- Administration ofthe compound can be systemic or local.
- Such therapeutic compounds include compounds that decrease the expression level of such gene that endogenously exists in the NSCLC cells (i.e., compounds that down-regulate the expression ofthe over-expressed gene(s), KIFll, GHSRlb and/or NTSRl genes).
- the administration of such therapeutic compounds counter the effects of aberrantly-over expressed gene(s) in the subjects NSCLC cells and are expected to improve the clinical condition ofthe subject.
- Such compounds can be obtained by the screening method ofthe present invention described above.
- the compounds that modulate the activity of a protein encoded by KIFll, GHSRlb, NTSRl or FOXMl gene that can be used for treating or preventing NSCLC ofthe present invention include besides proteins, naturally-occurring cognate ligand of these proteins, peptides, peptidomimetics and other small molecules.
- the expression of these over-expressed gene(s) can be inhibited by administering to the subject a nucleic acid that inhibits or antagonizes the expression ofthe over-expressed gene(s).
- Antisense oligonucleotides, siRNAs or ribozymes which disrupt the expression ofthe over-expressed gene(s) can be used for inhibiting the expression ofthe over-expressed gene(s).
- antisense-oligonucleotides corresponding to any ofthe nucleotide sequence of KIFll, GHSRlb, NTSRl or FOXMl gene can be used to reduce the expression level ofthe gene.
- Antisense-oligonucleotides corresponding to KIF 11 , GHSRl b, NTSRl , and FOXM 1 genes that are up-regulated in NSCLC are useful for the treatment or prevention of NSCLC.
- the antisense-oligonucleotides against the genes may act by binding to any ofthe corresponding polypeptides encoded by these genes, or mRNAs corresponding thereto, thereby inhibiting the transcription or translation ofthe genes, promoting the degradation ofthe mRNAs, and/or inhibiting the expression of proteins encoded by the KIFll, GHSRlb, NTSRl, and FOXMl nucleotides, and finally inhibiting the function ofthe proteins.
- antisense-oligonucleotides encompasses both nucleotides that are entirely complementary to the target sequence and those having a mismatch of one or more nucleotides, so long as the antisense-oligonucleotides can specifically hybridize to the target sequence.
- the antisense-oligonucleotides ofthe present invention include polynucleotides that have a homology (also referred to as sequence identity) of at least 70% or higher, preferably at 80% or higher, more preferably 90% or higher, even more preferably 95% or higher over a span of at least 15 continuous nucleotides up to the full length sequence of any ofthe nucleotide sequences of KIFl 1, GHSRlb, NTSRl or FOXMl gene.
- Algorithms known in the art can be used to determine the homology.
- derivatives or modified products ofthe antisense-oligonucleotides can also be used as antisense-oligonucleotides in the present invention.
- siRNA molecules ofthe invention can also be defined by their ability to hybridize specifically to mRNA or cDNA from the genes disclosed here.
- the terms “hybridize” or “hybridize specifically” are used to refer the ability of two nucleic acid molecules to hybridize under “stringent hybridization conditions.
- stringent hybridization conditions refers to conditions under which a nucleic acid molecule will hybridize to its target sequence, typically in a complex mixture of nucleic acids, but not detectably to other sequences.
- stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength pH.
- the T m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% ofthe probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T m , 50% ofthe probes are occupied at equilibrium).
- Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
- a positive signal is at least two times background, preferably 10 times background hybridization.
- Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 50°C
- the antisense-oligonucleotides and derivatives thereof act on cells producing the proteins encoded by KIFl 1, GHSRlb, NTSRl or FOXMl gene by binding to the DNA or mRNA encoding the protein, inhibiting transcription or translation thereof, promoting the degradation ofthe mRNAs and inhibiting the expression ofthe protein, thereby resulting in the inhibition ofthe protein function.
- An antisense-oligonucleotides and derivatives thereof can be made into an external preparation, such as a liniment or a poultice, by mixing with a suitable base material which is inactive against the derivative.
- the antisense-oligonucleotides ofthe invention inhibit the expression of at least one protein encoded by any one of KIFl 1, GHSRlb, NTSRl, and FOXMl genes, and thus are useful for suppressing the biological activity ofthe protein.
- the polynucleotides that inhibit one or more gene products of over-expressed genes also include small interfering RNAs (siRNA) comprising a combination of a sense strand nucleic acid and an antisense strand nucleic acid ofthe nucleotide sequence encoding an over-expressed protein encoded by KIFl 1, GHSRlb, NTSRl or FOXMl gene.
- siRNA refers to a double stranded RNA molecule which prevents translation of a target mRNA. Standard techniques of introducing siRNA into the cell can be used in the treatment or prevention ofthe present invention, including those in which DNA is a template from which RNA is transcribed.
- the siRNA is constructed such that a single transcript has both the sense and complementary antisense sequences from the target gene, e.g., a hairpin.
- the method is used to suppress gene expression of a cell with up-regulated expression of KIFll, GHSRlb, NTSRl or FOXMl gene. Binding ofthe siRNA to KIFll, GHSRlb, NTSRl or FOXMl gene transcript in the target cell results in a reduction of KIFl 1, GHSRlb, NTSRl or FOXMl protein production by the cell.
- the length ofthe oligonucleotide is at least about 10 nucleotides and may be as long as the naturally occurring transcript.
- the oligonucleotide is about 19 to about 25 nucleotides in length. Most preferably, the oligonucleotide is less than about 75, about 50 or about 25 nucleotides in length.
- Preferable siRNA ofthe present invention include the polynucleotides having the nucleotide sequence of SEQ ID NO: 32, 33, 34, 35, 36, 37, or 108 as the target sequence, which all proved to be effective for suppressing cell viability of NSCLC cell lines.
- a preferable siRNA used in the present invention has the general formula:
- GHSRlb, NTSRl or FOXMl is a ribonucleotide sequence consisting of about 3 to about 23 nucleotides; and [A'] is a ribonucleotide sequence complementary to [A].
- a target sequence of KIFll, GHSRlb, NTSRl or FOXMl gene refers to a sequence that, when introduced into NSCLC cell lines, is effective for suppressing cell viability.
- Preferred target sequence of KIFll, GHSRlb, NTSRl or FOXMl gene includes nucleotide sequences comprising: SEQ ID NOs: 32, 33, 34, 35, 36, 37, and 108.
- complementary sequence [A'] and [A] hybridize to each other to form a double strand, and the whole siRNA molecule with the general formula 5 '-[A]-[B]-[A']-3 ' forms a hairpin loop structure.
- the term "complementary" refers to a Watson-Crick or Hoogsteen base pairing between nucleotide units of a polynucleotide, and hybridization or binding of nucleotide units indicates physical or chemical interaction between the units under appropriate conditions to form a stable duplex (double-stranded configuration) containing few or no mismatches. In a preferred embodiment, such duplexes contain no more than 1 mismatch for every 10 base pairs.
- the siRNA against the mRNA of KIFl 1, GHSRlb, NTSRl or FOXMl gene to be used in the present invention contains a target sequence shorter than the whole mRNA of KIFll, GHSRlb, NTSRl or FOXMl gene, and has a sequence of 500, 200, or 75 nucleotides as the whole length. Also included in the invention is a vector containing one or more ofthe nucleic acids described herein, and a cell containing the vectors.
- the isolated nucleic acids ofthe present invention are useful for siRNA against KIFll, GHSRlb, NTSRl or FOXMl or DNA encoding the siRNA.
- the sense strand is preferably longer than about 19 nucleotides, and more preferably longer than about 21 nucleotides.
- the nucleotide sequence of siRNAs may be designed using a siRNA design computer program available from the Ambion website
- the nucleotide sequences for the siRNA are selected by the computer program based on the following protocol:
- siRNA Target Sites 1. Beginning with the AUG start codon of the transcript, scan downstream for AA dinucleotide sequences. Record the occurrence of each AA and the 3' adjacent 19 nucleotides as potential siRNA target sites. Tuschl, et al. Genes Dev 13(24): 3191-7 (1999), not recommend against designing siRNA against the 5' and 3' untranslated regions (UTRs) and regions near the start codon (within 75 bases) as these may be richer in regulatory protein binding sites, and thus the complex of endonuclease and siRNAs that were designed against these regions may interfere with the binding of UTR-binding proteins and or translation initiation complexes.
- UTRs untranslated regions
- the homology search can be performed using BLAST, which can be found on the NCBI server at: www.ncbi.nlm.nih.gov/BLAST/
- siRNAs inhibit the expression of over-expressed KIFll, GHSRlb, NTSRl or FOXMl protein and is thereby useful for suppressing the biological activity ofthe protein. Therefore, a composition comprising the siRNA is useful in treating or preventing non-small cell lung cancer.
- the nucleic acids that inhibit one or more gene products of over-expressed genes KIFl 1, GHSRlb, NTSRl, and FOXMl also include ribozymes against the gene(s).
- the ribozymes inhibit the expression of over-expressed KIFll, GHSRlb, NTSRl or FOXMl protein and is thereby useful for suppressing the biological activity ofthe protein. Therefore, a composition comprising the ribozyme is useful in treating or preventing NSCLC.
- ribozymes are classified into large ribozymes and small ribozymes.
- a large ribozyme is known as an enzyme that cleaves the phosphate ester bond of nucleic acids.
- the reacted site consists of a 5'-phosphate and 3 '-hydroxyl group.
- the large ribozyme is further classified into (1) group I intron RNA catalyzing transesterification at the 5'-splice site by guanosine; (2) group II intron RNA catalyzing self-splicing through a two step reaction via lariat structure; and (3) RNA component ofthe ribonuclease P that cleaves the tRNA precursor at the 5' site through hydrolysis.
- small ribozymes have a smaller size (about 40 bp) compared to the large ribozymes and cleave RNAs to generate a 5 '-hydroxyl group and a 2' -3' cyclic phosphate.
- Hammerhead type ribozymes (Koizumi et al, FEBS Lett. 228: 225 (1988)) and hairpin type ribozymes (Buzayan, Nature 323: 349 (1986); Kikuchi and Sasaki, Nucleic Acids Res. 19: 6751 (1992)) are included in the small ribozymes.
- ribozymes inhibiting the expression of an over-expressed NSC protein can be constructed based on the sequence information ofthe nucleotide sequence encoding KIFll, GHSRlb, NTSRl or FOXMl protein according to conventional methods for producing ribozymes.
- the ribozymes inhibit the expression of over-expressed KIFll, GHSRlb, NTSRl or FOXMl protein and is thereby useful for suppressing the biological activity ofthe protein. Therefore, a composition comprising the ribozyme is useful in treating or preventing NSCLC.
- the function of one or more gene products ofthe over-expressed genes is inhibited by administering a compound that binds to or otherwise inhibits the function ofthe gene products.
- the compound is an antibody which binds to the over-expressed gene product or gene products.
- the present invention refers to the use of antibodies, particularly antibodies against a protein encoded by any ofthe up-regulated genes KIFll, GHSRlb, NTSRl or FOXMl, or a fragment ofthe antibody.
- antibody refers to an immunoglobulin molecule having a specific structure that interacts (binds) specifically with a molecule comprising the antigen used for synthesizing the antibody (i.e., the up-regulated gene product) or with an antigen closely related to it.
- An antibody that binds to the over-expressed KIFl 1, GHSRlb, NTSRl or FOXMl nucleotide may be in any form, such as monoclonal or polyclonal antibodies, and includes antiserum obtained by immunizing an animal such as a rabbit with the polypeptide, all classes of polyclonal and monoclonal antibodies, human antibodies and humanized antibodies produced by genetic recombination.
- the antibody used in the method of treating or preventing NSCLC ofthe present invention may be a fragment of an antibody or a modified antibody, so long as it binds to one or more ofthe proteins encoded by the marker genes (KIFl 1, GHSRlb, NTSRl or FOXMl gene).
- the antibodies and antibody fragments used in the present method of treating or preventing NSCLC may be modified, and include chemically modified and chimeric antibodes.
- Such antibodies and antibody fragments can be obtained according to the above-mentioned methods, supra.
- a human antibody or a humanized antibody is preferable for reducing immunogenicity.
- transgenic animals having a repertory of human antibody genes may be immunized with an antigen such as KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide, cells expressing the polypeptide, or their lysates.
- Antibody producing cells are then collected from the animals and fused with myeloma cells to obtain hybridoma, from which human antibodies against the polypeptide can be prepared (see WO92-03918, WO93-2227, WO94-02602, WO94-25585, WO96-33735, and WO96-34096).
- an immune cell such as an immunized lymphocyte, producing antibodies may be immortalized by an oncogene and used for preparing monoclonal antibodies.
- the present invention provides a method for treating or preventing NSCLC, using an antibody against an over-expressed KIFll, GHSRlb, NTSRl or FOXMl polypeptide.
- a pharmaceutically effective amount of an antibody against KIFll, GHSRlb, NTSRl or FOXMl polypeptide is administered.
- An antibody against an over-expressed KIFll, GHSRlb, NTSRl or FOXMl polypeptide is administered at a dosage sufficient to reduce the activity of KIFl 1, GHSRlb, NTSRl or FOXMl protein.
- an antibody binding to a cell surface marker specific for tumor cells can be used as a tool for drug delivery.
- an antibody against an over-expressed KIFl 1, GHSRlb, NTSRl or FOXMl polypeptide conjugated with a cytotoxic agent may be administered at a dosage sufficient to injure tumor cells.
- dominant negative mutants ofthe proteins disclosed here can be used to treat or prevent NSCLC.
- fragments of KOCl that specifically bind KIFl 1 can be used.
- dominant negative fragment of KOCl is a mutated form of KOCl that is capable of complexing with either of KIF 11 and RNA to be transported such that the RNA transporter activity ofthe complex is diminished.
- a dominant negative fragment is one that is not functionally equivalent to the full length KOCl polypeptide.
- Preferred dominant negative fragments are those that comprise at least one RRM domain of KOC 1.
- the dominant negative fragments have two RRM domains and zero to three of KH domains.
- KOC1DEL2 (2xRRM+2xKH) and KOC1DEL3 (2xRRM without KH) are prefferable fragment for dominant negative effect.
- the amino acid sequences of KOC1DEL2 and KOC1DEL3 consist of positions 1 to 406 and 1-197 of SEQ ID NO:105, respectively.
- the fragments are typically less than about 300 amino acids, typically less than about 200 amino acids.
- the present invention also relates to a method of treating or preventing NSCLC in a subject comprising administering to said subject a vaccine comprising a polypeptide encoded by a nucleic acid selected from the group consisting of KIFll, GHSRlb, NTSRl, and FOXMl genes or an immunologically active fragment of said polypeptide, or a polynucleotide encoding the polypeptide or the fragment thereof.
- Administration of the polypeptide induces an anti-tumor immunity in a subject.
- the present invention further provides a method for inducing anti tumor immunity.
- the polypeptide or the immunologically active fragments thereof are useful as vaccines against NSCLC.
- the proteins or fragments thereof may be adniinistered in a form bound to the T cell receptor (TCR) or presented on an antigen presenting cell (APC), such as macrophage, dendritic cell (DC) or B-cells. Due to the strong antigen presenting ability of DC, the use of DC is most preferable among the APCs.
- TCR T cell receptor
- APC antigen presenting cell
- DC dendritic cell
- B-cells B-cells. Due to the strong antigen presenting ability of DC, the use of DC is most preferable among the APCs.
- the phrase "vaccine against NSCLC” refers to a substance that has the function to induce anti-tumor immunity or immunity to suppress NSCLC upon inoculation into animals.
- anti-tumor immunity includes immune responses such as follows:
- the protein when a certain protein induces any one of these immune responses upon inoculation into an animal, the protein is decided to have anti-tumor immunity inducing effect.
- the induction ofthe anti-tumor immunity by a protein can be detected by observing in vivo or in vitro the response ofthe immune system in the host against the protein.
- a method for detecting the induction of cytotoxic T lymphocytes is well known. A foreign substance that enters the living body is presented to T cells and B cells by the action of antigen presenting cells (APCs).
- T cells that respond to the antigen presented by APC in antigen specific manner differentiate into cytotoxic T cells (or cytotoxic T lymphocytes; CTLs) due to stimulation by the antigen, and then proliferate (this is referred to as activation of T cells). Therefore, CTL induction by a certain peptide can be evaluated by presenting the peptide to T cell by APC, and detecting the induction of CTL. Furthermore, APC has the effect of activating CD4+ T cells, CD8+ T cells, macrophages, eosinophils and NK cells. Since CD4+ T cells are also important in anti-tumor immunity, the anti-tumor immunity inducing action of the peptide can be evaluated using the activation effect of these cells as indicators.
- DC dendritic cells
- APC dendritic cells
- DC is a representative APC having the strongest CTL inducing action among APCs.
- the test polypeptide is initially contacted with DC and then this DC is contacted with T cells. Detection of T cells having cytotoxic effects against the cells of interest after the contact with DC shows that the test polypeptide has an activity of inducing the cytotoxic T cells.
- Activity of CTL against tumors can be detected, for example, using the lysis of 51 Cr-labeled tumor cells as the indicator.
- PBMCs peripheral blood mononuclear cells
- CTL The induction of CTL is reported to be enhanced by culturing PBMC in the presence of GM-CSF and IL-4. Similarly, CTL is shown to be induced by culturing PBMC in the presence of keyhole limpet hemocyanin (KLH) and IL-7.
- KLH keyhole limpet hemocyanin
- the test polypeptides confirmed to possess CTL inducing activity by these methods are polypeptides having DC activation effect and subsequent CTL inducing activity. Therefore, polypeptides that induce CTL against tumor cells are useful as vaccines against NSCLC.
- APC that acquired the ability to induce CTL against NSCLC by contacting with the polypeptides are useful as vaccines against NSCLC.
- CTL that acquired cytotoxicity due to presentation ofthe polypeptide antigens by APC can be also used as vaccines against NSCLC.
- Such therapeutic methods for NSCLC using anti-tumor immunity due to APC and CTL are referred to as cellular immunotherapy.
- efficiency ofthe CTL-induction is known to increase by combining a plurality of polypeptides having different structures and contacting them with DC. Therefore, when stimulating DC with protein fragments, it is advantageous to use a mixture of multiple types of fragments.
- the induction of anti-tumor immunity by a polypeptide can be confirmed by observing the induction of antibody production against tumors.
- the polypeptide when antibodies against a polypeptide are induced in a laboratory animal immunized with the polypeptide, and when growth, proliferation or metastasis of tumor cells is suppressed by those antibodies, the polypeptide can be determined to have an ability to induce anti-tumor immunity.
- Anti-tumor immunity is induced by administering the vaccine of this invention, and the induction of anti-tumor immunity enables treatment and prevention of NSCLC.
- Therapy against or prevention ofthe onset of NSCLC includes any ofthe steps, such as inhibition ofthe growth of NSCLC cells, involution of NSCLC cells and suppression of occurrence of NSCLC cells.
- NSCLC Decrease in mortality of individuals having NSCLC, decrease of marker genes (in addition to KIF 11 , GHSRl b and or NTSRl genes) in the blood, alleviation of detectable symptoms accompanying NSCLC and such are also included in the therapy or prevention of NSCLC.
- Such therapeutic and preventive effects are preferably statistically significant. For example, in observation, at a significance level of 5% or less, wherein the therapeutic or preventive effect of a vaccine against NSCLC is compared to a control without vaccine administration.
- Student's t-test, the Mann- Whitney U-test or ANOVA may be used for statistical analysis.
- the above-mentioned protein having immunological activity, or a polynucleotide or vector encoding the protein may be combined with an adjuvant.
- An adjuvant refers to a compound that enhances the immune response against the protein when administered together (or successively) with the protein having immunological activity.
- adjuvants include cholera toxin, salmonella toxin, alum and such, but are not limited thereto.
- the vaccine of this invention may be combined appropriately with a pharmaceutically acceptable carrier. Examples of such carriers are sterilized water, physiological saline, phosphate buffer, culture fluid and such.
- the vaccine may contain as necessary, stabilizers, suspensions, preservatives, surfactants and such. The vaccine is administered systemically or locally.
- Vaccine administration may be performed by single administration or boosted by multiple administrations.
- NSCLC can be treated or prevented, for example, by the ex vivo method. More specifically, PBMCs ofthe subject receiving treatment or prevention are collected, the cells are contacted with the polypeptide ex vivo, and following the induction of APC or CTL, the cells may be administered to the subject.
- APC can be also induced by introducing a vector encoding the polypeptide into PBMCs ex vivo.
- APC or CTL induced in vitro can be cloned prior to administration. By cloning and growing cells having high activity of damaging target cells, cellular immunotherapy can be performed more effectively.
- APC and CTL isolated in this manner may be used for cellular immunotherapy not only against individuals from whom the cells are derived, but also against similar types of diseases in other individuals.
- the present invention provides a method for treating or preventing NSCLC in a subject, wherein a compound obtained according to any ofthe above-described screening methods is administered to the subject. Any compound that are obtained according to any of the screening methods ofthe present invention can be administered to the subject so long as it decreases the expression or function, or both, of one or more gene products of KIFll, GHSRlb, NTSRl , and FOXMl genes. .
- siRNA and vectors encoding them Transfection of vectors expressing siRNA for KIFll, GHSRlb, NTSRl or FOXMl leads to growth inhibition of NSCLC cells.
- the double-stranded molecule ofthe present invention comprises a sense strand and an antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to a KIFll, GHSRlb, NTSRl or FOXMl target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said double-stranded molecule, and wherein said double-stranded molecule, when introduced into a cell expressing a KIFll, GHSRlb, NTSRl or FOXMl gene, inhibits expression of said gene.
- the double-stranded molecule ofthe present invention may be a polynucleotide derived from its original environment (i.e., when it is a naturally occurring molecule, the natural environment), physically or chemically altered from its natural state, or chemically synthesized.
- double-stranded molecules include those composed of DNA, RNA, and derivatives thereof.
- a DNA is suitably composed of bases such as A, T, C and G, and T is replaced by U in an RNA.
- the term "complementary” refers to a Watson-Crick or Hoogsteen base pairing between nucleotide units of a polynucleotide, and hybridization or binding of nucleotide units indicates physical or chemical interaction between the units under appropriate conditions to form a stable duplex (double-stranded configuration) containing few or no mismatches.
- such duplexes contain no more than 1 mismatch for every 10 base pairs.
- Particularly preferred duplexes are fully complementary and contain no mismatch.
- the double-stranded molecule ofthe present invention contains a ribonucleotide sequence corresponding to a KIFl 1, GHSRlb, NTSRl or FOXMl target sequence shorter than the whole mRNA of KIFl 1, GHSRlb, NTSRl or FOXMl gene.
- a target sequence of KIFll, GHSRlb, NTSRl or FOXMl gene refers to a sequence that, when introduced into NSCLC cell lines, is effective for suppressing cell viability.
- the target sequence comprises at least about 10, or suitably about 19 to about 25 contiguous nucleotides from the nucleotide sequences selected from the group of SEQ ID NOs: 1, 3, 5, and 106.
- the sense strand ofthe present double-stranded molecule consists of at least about 10 nucleotides, suitably is longer than 19 nucleotides, and more preferably longer than 21 nucleotides.
- Preferred target sequences include the sequences of SEQ ID NOs: 32, 33 tone 34, 35, 36, 37, and 108.
- the present double-stranded molecule including the sense strand and the antisense strand is an oligonucleotide shorter than about 100, preferably 75, more preferably 50 and most preferably 25 nucleotides in length.
- a suitable double-stranded molecule ofthe present invention is an oligonucleotide of a length of about 19 to about 25 nucleotides.
- nucleotide "u” can be added to 3 'end ofthe antisense strand ofthe target sequence.
- the number of "u”s to be added is at least 2, generally 2 to 10, preferably 2 to 5.
- the added "u”s form single strand at the 3 'end ofthe antisense strand ofthe siRNA.
- the siRNA molecules fo the invention are typically modified as described above for antisense molecules. Other modifications are also possible, for example, cholesterol-conjugated siRNAs have shown improved pharmacological properties (Song et al Nature Med. 9:347-351 (2003): ) .
- the double-stranded molecule ofthe present invention may be a single ribonucleotide transcript comprising the sense strand and the antisense strand linked via a single-stranded ribonucleotide sequence.
- the present double-stranded molecule may have the general formula: 5'-[A]-[B]-[A']-3' wherein [A] is a ribonucleotide sequence corresponding to a target sequence of KIFl 1, GHSRlb, NTSRl or FOXMl;
- [B] is a ribonucleotide sequence (loop sequence) consisting of 3 to 23 nucleotides.
- [A'] is a ribonucleotide sequence complementary to [A].
- the complementary sequence [A'] and [A] hybridize to each other to form a double strand, and the whole siRNA molecule with the general formula 5'-[A]-[B]-[A']-3' forms a hairpin loop structure.
- the region [A] hybridizes to [A'], and then a loop consisting of region [B] is formed.
- the loop sequence can be selected from those describe in http://www.ambion.com/techlib/tb/tb_506.html, or those described in Jacque, J.-M. et al, Nature 418 : 435-438 (2002). Additional examples of the loop sequence that can be included in the present double-stranded molecules include:
- CCC, CCACC or CCACACC Jacque, J. M. et al, Nature, Vol. 418: 435-438 (2002); UUCG: Lee, N.S. et al, Nature Biotechnology 20:500-505 (2002); Fruscoloni, P. et.al, Proc. Natl. Acad. Sci. USA 100(4): 1639-1644 (2003); and
- the loop sequence can be selected from the group consisting of: CCC, UUCG, CCACC, CCACACC, and UUCAAGAGA.
- the most preferable loop sequence is UUCAAGAGA (corresponding to "ttcaagaga” in a DNA): guuaguguac gaacuggag-[B]-cuccaguuc guacacuaac (for the target sequence of SEQ ID NO:32) gugucucugu uggagaucu-[B]-agaucucca acagagacac (for the target sequence of SEQ ID NO:33) gaaggcaguu gaccaacac-[B]-guguugguc aacugccuuc (for the target sequence of SEQ ID NO: 34) ccucuaccug uccagcaug-[B]-caugcugga cagguagagg (for the target sequence of SEQ ID NO:35) guucaucagc gccaucugg-[B]-ccagauggc gcugaugaac (forthe target sequence of SEQ ID NO:36) ggucgucaua
- the present invention further provides a vector encoding the double-stranded molecule ofthe present invention.
- the vector encodes a transcript having a secondary structure and which comprises the sense strand and the antisense strand, and suitably comprises a single-stranded ribonucleotide sequence linking said sense strand and said antisense strand.
- the vector preferably comprises a regulatory sequence adjacent to the region encoding the present double-stranded molecule that directs the expression ofthe molecule in an adequate cell.
- the double-stranded molecules ofthe present invention are intracellularly transcribed by cloning their coding sequence into a vector containing, e.g., a RNA pol III transcription unit from the small nuclear RNA (snRNA) U6 or the human HI RNA promoter.
- the present vectors are produced, for example, by cloning the target sequence into an expression vector so the objective sequence is operatively-linked to a regulatory sequence ofthe vector in a manner to allow expression thereof (transcription ofthe DNA molecule) (Lee, N.S. et al, Nature Biotechnology 20: 500-505 (2002)).
- the transcription of an RNA molecule having an antisense sequence to the target sequence is driven by a first promoter (e.g., a promoter sequence linked to the 3 '-end ofthe cloned DNA) and that having the sense strand to the target sequence by a second promoter (e.g., a promoter sequence linked to the 5'-end ofthe cloned DNA).
- the expressed sense and antisense strands hybridize to each other in vivo to generate a siRNA construct to silence a gene that comprises the target sequence.
- two constructs may be utilized to respectively produce the sense and anti-sense strands of a siRNA construct.
- transfection-enhancing agent can be used for introducing the vectors into a cell. FuGENE (Rochediagnostices), Lipofectamine 2000 (Invitrogen), Oligofectamine (Invitrogen), and Nucleofector (Wako pure Chemical) are useful as the transfection-enhancing agent.
- compositions for treating or preventing NSCLC comprising a compound selected by the present method of screening for a compound that alters the expression or activity of an NSCLC-associated gene.
- a compound isolated by the screening method ofthe present invention as a pharmaceutical for humans and other mammals, such as mice, rats, guinea-pig, rabbits, cats, dogs, sheep, pigs, cattle, monkeys, baboons or chimpanzees for treating a cell proliferative disease (e.g., non-small cell lung cancer)
- the isolated compound can be directly administered or can be formulated into a dosage form using conventional pharmaceutical preparation methods.
- Such pharmaceutical formulations ofthe present compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration, or for administration by inhalation or insufflation.
- the formulations are optionally packaged in discrete dosage units.
- Pharmaceutical formulations suitable for oral administration include capsules, cachets or tablets, each containing a predetermined amount ofthe active ingredient.
- Formulations also include powders, granules, solutions, suspensions or emulsions.
- the active ingredient is optionally administered as a bolus electuary or paste.
- Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrant or wetting agents.
- a tablet may be made by compression or molding, optionally with one or more formulational ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
- Molded tablets may be made via molding in a suitable machine a mixture ofthe powdered compound moistened with an inert liquid diluent. The tablets may be coated according to methods well known in the art.
- Oral fluid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle prior to use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils) or preservatives.
- the tablets may optionally be formulated so as to provide slow or controlled release ofthe active ingredient in vivo.
- a package of tablets may contain one tablet to be taken on each of the month. The formulation or dose of medicament in these preparations makes a suitable dosage within the indicated range acquirable.
- Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood ofthe intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition ofthe sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use. Alternatively, the formulations may be presented for continuous infusion.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets ofthe kind previously described.
- Formulations for rectal administration include suppositories with standard carriers such as cocoa butter or polyethylene glycol.
- Formulations for topical administration in the mouth include lozenges, which contain the active ingredient in a flavored base such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a base such as gelatin, glycerin, sucrose or acacia.
- a liquid spray or dispersible powder or in the form of drops may be used for intra-nasal administration of an active ingredient.
- Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents.
- the compositions are conveniently delivered from an insufflator, nebulizer, pressurized packs or other convenient means of delivering an aerosol spray.
- Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichiorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the compositions may take the form of a dry powder composition, for example, a powder mix of an active ingredient and a suitable powder base such as lactose or starch.
- the powder composition may be presented in unit dosage form in, for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflators.
- Other formulations include implantable devices and adhesive patches; which release a therapeutic agent. When desired, the above-described formulations, adapted to give sustained release ofthe active ingredient, may be employed.
- compositions may also contain other active ingredients such as antimicrobial agents, immunosuppressants or preservatives.
- active ingredients such as antimicrobial agents, immunosuppressants or preservatives.
- the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.
- Preferred unit dosage formulations are those containing an effective dose, as recited below, of the active ingredient or an appropriate fraction thereof.
- the compositions e.g., polypeptides and organic compounds are administered orally or via injection at a dose of from about 0.1 to about 250 mg/kg per day.
- the dose range for adult humans is generally from about 5 mg to about 17.5 g/day, preferably about 5 mg to about 10 g/day, and most preferably about 100 mg to about 3 g/day.
- Tablets or other unit dosage forms of presentation provided in discrete units may conveniently contain an amount which is effective at such dosage or as a multiple ofthe same, for instance, units containing about 5 mg to about 500 mg, usually from about 100 mg to about 500 mg.
- the dose employed will depend upon a number of factors, including the age and sex ofthe subject, the precise disorder being treated, and its severity. Also the route of administration may vary depending upon the condition and its severity.
- the present invention further provides a composition for treating or preventing NSCLC comprising active ingredient that inhibits the expression of any one ofthe gene selected from the group of KIFl 1, GHSRlb, NTSRl, and FOXMl genes.
- active ingredient can be an antisense-oligonucleotide, siRNA or ribozyme against the gene, or derivatives, such as expression vector, ofthe antisense-oligonucleotide, siRNA or ribozyme.
- the active ingredient may be made into an external preparation, such as liniment or a poultice, by mixing with a suitable base material which is inactive against the derivatives.
- the active ingredient can be formulated into tablets, powders, granules, capsules, liposome capsules, injections, solutions, nose-drops and freeze-drying agents by adding excipients, isotonic agents, solubilizers, preservatives, pain-killers and such.
- these can be prepared according to conventional methods for preparing nucleic acid containing pharmaceuticals.
- the antisense-oligonucleotide derivative, siRNA derivative or ribozyme derivative is given to the patient by direct application to the ailing site or by injection into a blood vessel so that it will reach the site of ailment.
- a mounting medium can also be used in the composition to increase durability and membrane-permiability.
- mounting mediums include liposome, poly-L-lysine, lipid, cholesterol, lipofectin and derivatives thereof.
- the dosage of such compositions can be adjusted suitably according to the patient's condition and used in desired amounts. For example, a dose range of 0.1 to 100 mg/kg, preferably 0.1 to 50 mg/kg can be administered.
- Another embodiment ofthe present invention is a composition for treating or preventing NSCLC comprising an antibody against a polypeptide encoded by any one ofthe genes selected from the group of KIFl 1, GHSRlb, NTSRl, and FOXMl genes or fragments ofthe antibody that bind to the polypeptide.
- the dose of an antibody or fragments thereof for treating or preventing NSCLC is about 0.1 mg to about 100 mg per day, preferably about 1.0 mg to about 50 mg per day and more preferably about 1.0 mg to about 20 mg per day, when administered orally to a normal adult (weight 60 kg).
- a normal adult weight 60 kg
- NMU2R 5'- GGCTCTTACAACTCATGTACCCA-3' (SEQ.ID.NO.15) and 5'-TGATACAGAGACATGAAGTGAGCA-3' (SEQ.ID.NO.16); GHSRla, 5'-TGGTGTTTGCCTTCATCCT-3' (SEQ.ID.NO.17) and 5'-GAATCCCAGAAGTCTGAACA-3 ' (SEQ.ID.NO.18); GHSRlb, 5'-ACGGTCCTCTACAGTCTCA-3' (SEQ.ID.NO.19) and 5'-CACAGGGAGAGGATAGGA-3' (SEQ.ID.NO.20); NTSRl, 5'-AGTGGGCTCAGAGTCTAGCAAAT-3' (SEQ.ID.NO.21) and 5'-TATTGAGAGATACACGGGGTTTG-3' (SEQ.ID.NO.22); GHRL, 5'-TGAGCCCTGAACACCAGAGAG-3' (SEQ.ID.NO
- NTS 5'-TCTTCAGCATGATGTGTTGTGT-3' (SEQ.ID.NO.25) and 5'-TGAGAGATTCATGAGGAAGTCTTG-3' (SEQ.ID.NO.26); ACTB, 5'-GAGGTGATAGCATTGCTTTCG-3' (SEQ.ID.NO.27) and 5'-CAAGTCAGTGTACAGGTAAGC-3' (SEQ.ID.NO.28).
- PCR reactions were optimized for the number of cycles to ensure product intensity within the logarithmic phase of amplification.
- KOCl full-length
- KIFll partial amino acid sequence corresponding to codons 361-1056
- TALON resin BD Biosciences Clontech
- Affinity-purified anti-KOCl and anti-KIFll antibodies were used for western-blot analysis, immunoprecipitation, and immunostaining.
- Construction of KOCl deletion mutants and immunoprecipitation assays for identification o the KOC1-KIF11 binding region KOCl and several of its domains Fig.
- RNA-immunoprecipitation and cDNA microarray screening for identification of KOCl-associated mRNAs We adopted the RNA immunoprecipitation protocol of Niranjanakumari et al.( Niranjanakumari, S. et al. Methods 26, 182-190 (2002)) to analyze RNA-protein interactions involving KOCl in vivo. Immunoprecipitated RNAs were isolated from five lung-cancer cell lines (A549, LC319, PC14, RERF-LC-AI, and SK-MES-1).
- RNAs T7 -based amplified RNAs
- IP-RNA immunoprecipiated RNA
- control total RNA
- Cy5-dCTP Cy5-dCTP
- Cy3-dCTP Cy5-dCTP
- IP-microarray analysis a cDNA microarray representing 32,256 genes
- the membrane was then blocked for 1 hour at room temperature in blocking buffer (10 mM Tris-HCl (pH 7.8), 150 mM NaCl, 1 mg/ml yeast tRNA), and washed twice with 50 ml of 10 mM Tris-HCl (pH 7.8) for 5 min and incubated with DIG-labeled RNA probe in 5 ml of NWB buffer (10 mM Tris-HCl (pH 7.8), 1 mM EDTA, 50 mM NaCl, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% BSA) for 2 hours at room temperature.
- the membrane was washed four times with NWB buffer and the RNA probe bound to the proteins was then detected using DIG nucleic acid detection kit (Roche) according to the supplier's protocol.
- Plasmids expressing ECFP-fused KOCl (ECFP-KOC1) protein were prepared using pECFP-Nl vectors (BD Biosciences Clontech). Plasmids expressing EYFP-fused KIFl 1 (EYFP-KIF11) protein were also prepared, using pEYFP-Nl vectors (BD Biosciences Clontech).
- Time-lapse images of COS-7 cells transfected with plasmids expressing ECFP-KOC1 or EYFP -KIFll proteins were captured for 5-15 hours by the Live Cell Imaging System (Power LX81, OLYMPUS) and a confocal microscope (TCS SP2-AOBS, Leica Microsystems; FV1000 FLUOVIEW, OLYMPUS).
- TCS SP2-AOBS Leica Microsystems
- FV1000 FLUOVIEW OLYMPUS
- In vitro transcription of linearized plasmids carrying the full-length cDNA sequence of an KOCl-associated gene, RAB35 was performed using DAVIS Lab's protocol (http://www.ed.ac.uk/ ⁇ ilan).
- plasmids were transcribed using the mCAP RNA capping kit (Stratagene) in the presence of Alexa Fluor 546-labeled UTP (Molecular Probes).
- mCAP RNA capping kit (Stratagene) in the presence of Alexa Fluor 546-labeled UTP (Molecular Probes).
- EGFP-KOC1 EGFP-fused KOCl
- COS-7 cells that had been transfected initially with pEGFP-i ⁇ OCi were additionally transfected 36 hours later with Alexa Fluor 546-labeled RAB35 mRNA (3 ⁇ g per 3.5-cm culture dish) in the presence of RNase Inhibitor (TAKARA).
- TAKARA RNase Inhibitor
- the plasmid-DNA and RNA samples were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocols. The cells were washed twice with PBS, and fresh medium was added 90 min after transfection with the labeled mRNA.
- the cells were allowed to recover in the incubator (37°C, 5% C ⁇ ) for 30 min before live-cell imaging for 3-6 hours with a confocal microscope (FN1000 FLUONIEW, OLYMPUS).
- a confocal microscope FN1000 FLUONIEW, OLYMPUS.
- COS-7-derived cells the COS-7 cells transfected with pEGFP-JTOC/ and Alexa Fluor 546-labeled RAB35 mR ⁇ A and the other, parental C ⁇ S-7 cells simply labeled with CellTracker (Molecular Probes) according to the supplier's protocols. These two cell populations were mixed and co-cultured for 12 hours before live-cell imaging with confocal microscope for 6 hours.
- COS-7-derived cell To investigate the translation ofthe mR ⁇ A transported by KOC1-R ⁇ P complex in the recipient cells, we prepared two types of COS-7-derived cell; one type was COS-7 cells co-transfected with pCAGGS-FLAG tagged-XOCi and -KIFll. After 24 hours culture, plasmid containing EGFP-fused RAB35 full length mR ⁇ A were re-transfected into these cells. The other type was C ⁇ S-7 cells simply labeled with CellTracker (blue). These two cell-types were mixed and co-cultured for 24 hours before live-cell imaging with video microscope for 12 hours.
- DIG-labeled probes complementary to RAB35 or EGFP mR ⁇ A were washed, mounted and visualized on light microscope. Fixed cells were hybridized with a mixture of DIG-labeled complementary to RAB35 mR ⁇ A for 16 hours in 50% formamide/ 2X SSC at 42°C Cells were washed, mounted and visualized on confocal microscope.
- RNA interference assay To prepare plasmid vector expressing short interfering RNA (siRNA), we amplified the genomic fragment of HI RNA gene containing its promoter region by PCR using a set of primers, 5'-TGGTAGCCAAGTGCAGGTTATA-3 ' (SEQ ID No: 44), and
- the BamHl and Xhol fragment containing H1RNA was into pcDNA3.1(+) between nucleotides 1257 and 56, and the fragment was amplified by PCR using 5'-TGCGGATCCAGAGCAGATTGTACTGAGAGT-3' (SEQ ID No: 46) and 5'- CTCTATCTCGAGTGAGGCGGAAAGAACCA-3' (SEQ ID No: 47), The ligated DNA became the template for PCR amplification with primers, 5'- TTTAAGCTTGAAGACCATTTTTGGAAAAAAAAAA ⁇ AAAAAAAAAAAC-3' (SEQ ID No: 48) and 5'-TTTAAGCTTGAAGACATGGGAAAGAGTGGTCTCA-3' (SEQ ID No: 49).
- the product was digested with Hin ⁇ lH, and subsequently self-ligated to produce psiHlBX3.0 vector plasmid having a nucleotide sequence shown in SEQ ID NO: 50.
- the DNAflagment encoding siRNA was inserted into the GAP at nucleotide 489-492 as indicated (-) in the following plasmid sequence (SEQ ID NO: 50).
- siRNA-expression vector lO ⁇ g of siRNA-expression vector were transfected into NSCLC cell lines, A549 and LC319, both endogenously over-expressing KOCl, KIFll, NMU, GHSRlb, NTSRl, RAB35, and FOXMl. More than 90% ofthe transfected cells expressed the synthetic siRNAs, and endogenous expression of target genes (KIFl 1, GHSRlb, NTSRl, RAB35, or FOXMl) in these cells was effectively suppressed.
- target genes KIFl 1, GHSRlb, NTSRl, RAB35, or FOXMl
- the transfected cells were cultured for five days in the presence of appropriate concentrations of geneticin (G418), and then, cell numbers and viability were measured by Giemsa staining and triplicate MTT assays.
- the target sequences ofthe synthetic oligonucleotides for RNAi were as follows: control 1 (EGFP: enhanced green fluorescent protein (EGFP) gene, a mutant of Aequorea victoria EGFP), 5'-GAAGCAGCACGACTTCTTC-3' (SEQ.ID.NO.29); control 2 (Luciferase: Photinus pyralis luciferase gene), 5'-CGTACGCGGAATACTTCGA-3' (SEQ.ID.NO.30); control 3 (Scramble: chloroplast Euglena gracilis gene coding for 5S and 16S rRNAs), 5'-GCGCGCTTTGTAGGATTCG-3' (SEQ.ID.NO.31); siRNA-KIFll-1 (#1), 5'
- oligonucleotides used for these siRNAs are shown below. Each constructs were prepared by cloning the following double-stranded oligonucleotide into the Bbsl site in the psiHlBX3.0 vector. The corresponding nucleotide position relative to the KIFl 1 , GHSRlb, NTSRl,
- RAB35 and FOXMl nucleic acid sequence of SEQ ID NOs:l, 3, 5, 112, and 106 are listed for each oligonucleotide sequence.
- Each oligonucleotide is a combination of a sense nucleotide sequence and an antisense nucleotide sequence ofthe target sequence of KIFll, GHSRlb, NTSRl, RAB35 and FOXMl.
- the nucleotide sequences ofthe hairpin loop structure of each siRNAs are also shown bellow, (endonuclease recognition sites are eliminated from each hairpin loop structure sequence).
- KIFll sil 288-306 (for the target sequence of gttagtgtac gaactggag/ SEQ ID NO:32) (insert F) Tccc gttagtgtacgaactggag ttcaagaga ctccagttcgtacactaac/SEQ ID NO: 51 (insert R) Aaaa gttagtgtacgaactggag tctcttgaa ctccagttcgtacactaac/SEQ ID NO:52 (hairpin) gttagtgtacgaactggag ttcaagaga ctccagttcgtacactaac/SEQ ID NO:53
- KIFll si2 612-630 (for the target sequence of gtgtctctgt tggagatct/ SEQ ID NO:33)
- insert F Tccc gtgtctctgt tggagatct ttcaagaga agatctccaacagagacac/SEQ ID NO: 54
- insert R Aaaa gtgtctctgt tggagatct tctctgaa agatctccaacagagacac/SEQ ID NO:55
- hairpin gtgtctctgt tggagatct tcaagaga agatctccaacagagacac/SEQ ID NO: 56
- KIFll si3 1700-1718 (for the target sequence of gaaggcagtt gaccaacac/ SEQ ID NO:34) (insert F) Tccc gaaggcagtt gaccaacac ttcaagaga gtgttggtcaactgccttc/SEQ ID NO:57 (insert R) Aaaa gaaggcagtt gaccaacac tctcttgaa gtgttggtcaactgccttc/SEQ ID NO:58 (hairpin) gaaggcagtt gaccaacac ttcaagaga gtgttggtcaactgccttc/SEQ ID NO: 59
- GHSRlb sil 237-255 (for the target sequence of cctctacctg tccagcatg/ SEQ ID NO:35) (insert F) Tccc cctctacctg tccagcatg ttcaagaga catgctggacaggtagagg/SEQ ID NO: 60 (insert R) Aaaa cctctacctg tccagcatg tctcttgaa catgctggacaggtagagg/SEQ ID NO:61 (hairpin) cctctacctg tccagcatg ttcaagaga catgctggacaggtagagg/SEQ ID NO: 62 NTSRl sil 933-951 (for the target sequence of gttcatcagc gccatctgg/ SEQ ID NO:36) (insert F) Tccc gttcatcagc gccatct
- NTSRl si2 1074-1092 (for the target sequence of ggtcgtcata caggtcaac/ SEQ ID NO:37) (insert F) Tccc ggtcgtcata caggtcaac ttcaagaga gttgacctgtatgacgacc/SEQ ID NO: 66 • (insert R) Aaaa ggtcgtcata caggtcaac tctcttgaa gttgacctgtatgacgacc/SEQ ID NO: 67 (hairpin) ggtcgtcata caggtcaac ttcaagaga gttgacctgtatgacgacc/SEQ ID NO:68
- RAB35 si 620-638 (for the target sequence of gagatgttca actgcatca/ SEQ ID NO:114) (insert F) Tccc gagatgttca actgcatca ttcaagaga tgatgcagt tgaacatctc/SEQ ID NO:l 15 (insert R) Aaaa gagatgttca actgcatca tctcttgaa tgatgcagt tgaacatctc /SEQ ID NO : 116 (hairpin) gagatgttca actgcatca ttcaagaga tgatgcagt tgaacatctc /SEQ ID NO:l 17
- FOXMl si 1240-1258 (for the target sequence of gcagcagaaacgaccgaat/ SEQ ID NO: 108) (insert F) Tccc gcagcagaaa cgaccgaat ttcaagaga attcggtcg tttctgctgc /SEQ ID NO: 109 (insert R) Aaaa gcagcagaaa cgaccgaat tctcttgaa attcggtcg ttctgctgc /SEQ ID NO:l 10 (hairpin) gcagcagaaa cgaccgaat ttcaagaga attcggtcg ttctgctgc /SEQ ID NO: 111.
- RNAi system ofthe present invention individual control siRNAs (EGFP, Luciferase, and Scramble) were initially confirmed using semiquantitative RT-PCR to decrease the expression ofthe corresponding target genes that had been transiently transfected into COS-7 cells.
- KOC1DEL3 and KOC1DEL2 construct Fig. 3a; 10 ⁇ g
- mock plasmid 10 ⁇ g
- plasmid mixtures of both constructs in the final dose of 10- ⁇ g DNA KOC1DEL3 or KOC1DEL2 vs mock ( ⁇ g), 7.5 : 2.5; 5 : 5; or 2.5 : 7.5, individually
- the transfected cells were cultured for 7 days in the presence of G418 and their viability was measured by triplicate MTT assays.
- Extracts were centrifuged at 14,000 rpm for 15 min, and supernatants were subjected to immunoprecipitation using anti-Flag M2 agarose (Sigma- Aldrich) and anti-HA beads (Sigma- Aldrich) for 1-2 hours.
- the beads were washed six times with IP-buffer, and protein was eluted by boiling the beads in Laemmli sample buffer after removing the final wash fraction. The eluted protein was resolved by SDS-PAGE and stained with silver staining.
- a 125 kDa-band was extracted by gel extraction, and used for mass spectrometric sequencing using MALDI-TOF mass spectrometry. This analysis identified KIFl 1 as the 125 kDa product.
- A549 cells were transiently co-transfected with Flag-tagged KIFll and myc-tagged KOCl and the cells were immunoprecipitated with anti-Flag M2 agarose. Subsequently, the cells were immunoblotted with anti-myc antibody (9E10; Santa Cruz). Next, using the same combination of vectors and cells, the cells were immunoprecipitated with anti-myc agarose (SIGMA) and immunoblotted with anti-Flag M2 antibody (Sigma-Aldrich).
- A549 cells were transiently co-transfected with Flag-tagged KIFll and myc-tagged KOCl, and co-localization of FITC-labeled KIFll and rhodamine-labeled KOC 1 mainly in the cytoplasm was detected by immunocytochemical staining using FITC-labeled anti-FLAG antibody and rhodamine-labeled anti-myc antibody, as described below.
- Immunocvtochemistry A549 cells grown on coverslips were cultured for 24 hours after passage, and were co-transfected with Flag-tagged KIF 11 and myc-tagged KOC 1. After 24-hours incubation, the cells were fixed with acetone/methanol (1:1) for 5 min on ice, blocked in CAS BLOCK (ZYMED) for 7 min at RT, and then incubated with rabbit anti-Flag polyclonal antibody (SIGMA) for 1 hour at RT. The fixed cells were washed 3 times with PBS, reacted with anti-rabbit IgG-FITC for 1 hour at RT. Then the cells were blocked again, and incubated with anti-myc antibody (9E10; Santa Cruz) for 1 hour at RT. Finally anti-mouse IgG-rhodamin was applied to the cells for 1 hour at RT. The cells were viewed on a Leica TCS SP2-AOBS confocal microscope.
- NTSRl the following experiments were performed.
- the entire coding region of each receptor gene was amplified by RT-PCR using primers
- GHSRla (5'-GGAATTCCATGTGGAACGCGACGCCCAGCGAA-3' (SEQ.ID.NO.38) and 5'-CGCGGATCCGCGTGTATTAATACTAGATTCTGTCCAGGCC-3' (SEQ.ID.NO.39)
- GHSRlb (5'-GGAATTCCATGTGGAACGCGACGCCCAGCGAA-3' (SEQ.ID.NO.40) and 5'-CGCGGATCCGCGGAGAGAAGGGAGAAGGCACAGGGA-3' (SEQ.ID.NO.41)
- NTSRl (5'-GGAATTCCATGCGCCTCAACAGCTCCGCGCCGGGAA-3' (SEQ.ID.NO.42) and 5'-CGCGGATCCGCGGTACAGCGTCTCGCGGGTGGCATTGCT-3 ' (SEQ.ID.NO.43)).
- COS-7 cells were transfected with GHSRlb or ⁇ TSR1 expression plasmids using FuGE ⁇ E6, as described above.
- Transfected COS-7 cells were cultured with 0.5 ⁇ M rhodamine-labeled NMU-25 peptide (NMU-25-rhodamine: Phoenix Pharmaceuticals. Inc.) for 12 hours, washed five times in PBS(-), and fixed in 4% paraformaldehyde solution for 60 min at room temperature.
- COS-7 cells transfected with GHSRla, GHSRl, or NTSRl without NMU-25 -rhodamine were transfected with GHSRla, GHSRl, or NTSRl without NMU-25 -rhodamine.
- COS-7 cells transfected with a known NMU receptor (NMUIR) served as a positive control for the assay.
- NMUIR NMU receptor
- COS-7 cells were plated at a density of 1 X 105 cells/100-mm dish and transfected with either GHSRlb, NTSRl, or NMUIR expression vectors; 24 hours after transfection, cells were incubated with 0.5 ⁇ M NMU-25-rhodamine for 12 hours, washed, trypsinized, collected in PBS, and washed once more in PBS. The population of cells binding to rhodamine-labeled NMU-25 was determined by flow cytometry. To further confirm binding of NMU-25 to the endogenous candidate receptors on the NSCLC cells, we performed receptor-ligand binding assay using the LC319 and PC-14 cells.
- these cells trypsinized were seeded onto 96-well black-wall, clear-bottom microtiter plates 24 hours prior to the assay.
- the medium was removed and the cells were incubated with Cy5 -NMU-25 with a 10-fold excess of unlabeled competitor.
- the plate was incubated in the dark for 24 hours at 37°C and was scanned on the 8200 Cellular Detection System (Applied Biosystems). 8200 Analysis Software creates a digitized gray scale image, quantitates the amount of fluorescence bound on the surface of each cell, and enumerates the fluorescent cells.
- cAMP levels Trypsinized LC319 cells were seeded onto 96-well microtiter plate (5.0 x 10 4 cells) and cultured in 10% FCS (+) RPMI-1640 medium for 24 hours, and then medium was changed to serum free RPMI-1640 medium / 1 mM IBMX (isobutylmethylxanthine) for 20 min prior to assay. Cells were incubated with NMU-25 peptides for 20 min prior to measuring the cAMP level using the cAMP EIA System (Amersham Biosystems).
- Intracellular Ca 2+ mobilization assay Trypsinized LC319 cells were seeded onto poly-D-lysine coated 384- well black- wall, clear-bottom microtiter plate (1.0 x 10 4 cells/ml) 24 hours prior to assay. Cells were loaded for 1 hour with 1 mM Fluo-4-AM fluorescent indicator dye in assay buffer (Hank's balanced salts solution, 20 mM HEPES, 2.5 mM probenecid), washed three times with assay buffer, and then returned to the incubator for 10 min before assay on a fluorometric imaging plate reader (FLIPR, Molecular Devices). Maximum change in fluorescence over base line was used to determine the response ofthe cells to the NMU-25 peptides stimulation.
- FLIPR Fluometric imaging plate reader
- control siRNA mRNAs were extracted 12, 24, and 36 hours after transfection, labelled with Cy5 or Cy3 dye and subjected to co-hybridization onto cDN A microarray slides containing 32,256 genes as described (Kakiuchi, S., et al, (2004). Hum. Mol. Genet. 13, 3029-3043., Ochi, K. et al, (2004). Int. J. Oncol. 24, 647-655.). After normalization ofthe data, genes with signals higher than the cut-off value were analyzed further. Genes whose intensity were significantly decreased in accordance with the time-dependent reduction of NMU expression were initially selected using SOM cluster analysis.
- LOC134145 (5'-CCACCATAACAGTGGAGTGGG-3' (SEQ.ID.NO.124) (5'-CAGTTACAGGTGTATGACTGGGAG-3' (SEQ.ID.NO.125)), NUP188 (5'-CTGAATACAACTTCCTGTTTGCC-3' (SEQ.ID.NO.126) and (5'-GACCACAGAATTACCAAAACTGC-3' (SEQ.ID.NO.127)).
- Expression ofthe candidate genes was additionally detected by semiquantitative RT-PCR using mRNAs isolated at 72 and 96 hours from LC319 cells treated with 1 ⁇ M NMU-25 or BSA at the time point of 0 and 48 hours.
- KIFll expression in NSCLC Validation of KIF 11 expression was performed in primary NSCLCs (clinical samples) and lung cancer cell lines. Increased KIFl 1 expression was confirmed in 12 of 16 NSCLC cases (5 of 8 ADCs and in 7 of 8 SCCs. In addition, up-regulation of KIFl 1 were observed in 14 of the 15 NSCLC cell lines.
- KIFll expression in normal human tissues Northern blotting with KIFl 1 cDNA as a probe identified 4.5- and 5.5-kb transcripts as very weak bands, only seen in placenta, testis, and bone marrow, among the 23 normal human tissues examined.
- the reported cDNA sequence of KIFll was considered to correspond to the larger transcript.
- To investigate the transcript corresponding to the smaller band we reversely transcribed mRNAs isolated from tissues ofthe testis and NSCLC cell lines. We amplified the entire sequence of KIFll cDNA by PCR using four primer sets, but found no alternatively-spliced transcript in these samples. Therefore, the smaller band may reflect cross-hybridization to the transcript of some related gene(s).
- the expression pattern of KIFll in normal human tissues was significantly correlated with that of KOCl (Fig. 2c).
- Isolation of mRNAs associated with the KOC1-KIF11 complex using RNA-irnmunoprecipitation and cDNA microarray KOCl protein is known to exhibit multiple attachments to IGF2 leader-3 mRNA, possibly through its two functional RRMs and four K-homologous (KH) domains (Nielsen, J. et al, Mol. Cell Biol. 19, 1262- 1270 (1999).).
- KH K-homologous domains
- IP-RT-PCR beta-actin
- RNA-immunoprecipitation we precipitated mRNAs using normal rabbit IgG and five NSCLC cell lines, and confirmed that none of eight KOCl associated mRNAs tested (CCT2, SBP2, SLC25A3, RAB35, PSMB7, GL, PKP4, and WINS 1) was precipitated by normal rabbit IgG.
- KOCl associated mRNAs tested CCT2, SBP2, SLC25A3, RAB35, PSMB7, GL, PKP4, and WINS 1
- beta-actin mRNA is transported to the leading lamellae of chicken-embryo fibroblasts (CEFs) and to the growth cones of developing neurons (Lawrence, .B. & Singer, R.H. Cell 45, 407-415 (1986); Bassell, GJ. et al, J. Neurosci. 18, 251-265 (1998)).
- the localization of ACTB mRNA depends on the "zipcode", a cis-acting element in the 3' UTR ofthe mRNA (Kislauskis, E.H.
- ZBPl zipcode-binding protein 1
- ZBPl -like proteins contain two RRMs in the N-terminal region and four hnRNP KH (ribonucleoprotein K-homology) domains at the C-terminal end.
- KOCl one ofthe IGF2 mRNA-binding proteins, is considered to be a member ofthe ZBPl family; it exhibits multiple attachments to IGF2 leader-3 mRNA (Nielsen, J. et al, Mol. Cell Biol. 19, 1262-1270 (1999)) and is over-expressed in several types of cancers (Mueller-Pillasch, F.
- RNA-immunoprecipitation experiments coupled with cDNA microarrays (IP-microarray)
- IP-microarray we identified dozens of candidate mRNAs that were likely to be associated with KOCl in NSCLC cells (see Table2). That list included genes encoding proteins with functions of cell-adhesion (PKP4, L1CAM1), cancer-cell progression and invasion (IGFBP2), and binding of small GTPs (RAB35), (Papagerakis, S. et al, Hum. Pathol.34, 565-572 (2003); Fogel, M. et al, Cancer Lett. 189, 237-247 (2003); Wang, H. et al, Cancer Res. 63, 4315-4321 (2003); Zhao, H. et al,
- Probe sets are ranked by the sum(*) of the fold change value (IP-mRNA / input RNA) of all five cell lines.
- na not annotated
- N/C negative control
- the KOC1DEL4 which is a construct with only the four KH domains and the KOC1DEL2
- a construct without C-terminal two KH domains showed very weak binding affinities for mRNAs compared to the fuU-lengthKOCl construct (Fig. 4b), suggesting the importance of two RRMs as well as of C-terminal two KH domains for binding to KOCl-associated mRNAs.
- KOCl -KIFl 1 RNP complex green particle
- Movement ofthe KOCl-KIFll complex appeared to be unidirectional from one cell to another.
- KOCl-KIFll complex could specifically transport KOCl-associated-mRNAs from one cell having a high level of KOCl -RNP complex to another having a lower level ofthe complex
- COS-7 cells that had been transfected with pEGFP -KOCl (green) as well as Alexa Fluor 546-labeled full-length RAB35 mRNA (red)
- parental COS-7 cells simply labeled with CellTracker (blue).
- KOCl particles green
- RNP particles of KOCl -RAB35 mRNA yellow
- SIGMA microtubule disrupting agent nocodazole
- DCTNl is the largest subunit of DCTN, which binds to the cytoplasmic motor-protein dynein and activates vesicle transport along microtubules (Holzbaur, E.L. & Tokito, M.K. Genomics 31, 398-399 (1996); Tokito, M.K. et al, Mol. Biol.
- A549 cells with 150 ⁇ M monastrol (SIGMA) for 24 hours induced the accumulation of endogenous KIFl 1 and exogenous EYFP-KIF11 at the center of monoaster along microtubules and the cell cycle arrest in mitosis with monopolar spindles, which is called "monoastral spindle”.
- Treatment of A549 cells with 150 ⁇ M of monastrol for 24 hours induced cell cycle arrest for mitotic cells with monopolar spindles that is called “monoastral spindle” and also caused accumulation of endogenous KIFll at the center of monoaster along microtubules.
- Dynein-DCTN interaction is probably a key component ofthe mechanism of axonal transport of vesicles and organelles (Holzbaur, E.L. & Tokito, M.K. Genomics 31, 398-399 (1996); Tokito, M.K.et /., Mol. Biol. Cell 7, 1167-1180 (1996)).
- the binding of DCTN to dynein is reportedly critical for neuronal function, since antibodies that specifically disrupt this binding block vesicle motility along microtubules.
- In vitro interaction of DCTNl and KIFll, and their co-localization during mitosis have been observed (Blangy, A. et al, J. Biol. Chem.
- NMUIR FM3/GPR66
- NMU2R FM4
- NMU2R is located only in brain.
- NMUIR and NMU2R genes were expressed in NSCLCs, expression of these NMU receptors were analyzed in normal human brain and lung, in NSCLC cell lines, and in clinical tissues by semiquantitative RT-PCR experiments. Neither NMUIR nor NMU2R expression was detected in any ofthe cell lines or clinical samples examined, although NMUIR was expressed in lung and NMU2R in brain (data now shown), suggesting that NMU could be mediating growth of lung-cancer cells through interaction with other receptor(s).
- NMU2R and NMUIR were originally isolated as homologues of known neuropeptide GPCRs, unidentified NMU receptor(s) were speculated to be members ofthe same family that would show some degree of homology to NMU1R/NMU2R. Hence, candidate NMU receptors were searched using the BLAST program.
- GHSR has two transcripts, types la and lb.
- the full-length human type la cDNA encodes a predicted polypeptide of 366 amino acids with seven transmembrane domains, a typical feature of G protein-coupled receptors.
- a single intron divides its open reading frame into two exons encoding transmembrane domains 1-5 and 6-7, thus placing the GHSRla into the intron-containing class of GPCRs.
- Type lb is a non-spliced mRNA variant transcribed from a single exon that encodes a polypeptide of 289 amino acids with five transmembrane domains. The semiquantitative RT-PCR analysis using specific primers for each variant indicated that GHSRl a was not expressed in NSCLCs.
- GHSRlb and NTSRl were expressed at a relatively high level in some NSCLC cell lines, but not at all in normal lung (Fig. 13a).
- the GHSRlb product has 46% homology to NMUIR, and NTSRl encodes 418 amino acids with 47% homology to NMUIR.
- Identification of candidate receptors for NMU in NSCLC To confirm direct interaction between NMU and GHSRlb/NTSRl, COS-7 cells were transiently transfected with plasmids designed to express FLAG-tagged GHSRlb or NTSRl, and cultured in the presence of rhodamine-labeled NMU-25.
- GHSRlb expression in normal human tissues As the expression of GHSRlb in normal human tissues was not precisely reported at the time, the distribution of GHSRlb was determined using human multiple tissue Northern-blot.
- Northern blotting with GHSRlb cDNA as a probe identified a 0.9-kb transcript as a very weak signal band in comparison with a 1.1 -kb transcript GHSRl a, seen in the heart, liver, skeletal muscle, pancreas, and stomach, among the 23 normal human tissues examined (Fig. 13b).
- receptor-ligand binding assay using the LC319 and PC-14 cells treated with NMU-25.
- SOM clustering is data nrining and visualization method originally developed by Kohonen (Kohonen, T. (1990). The self-organizing map. IEEE 78, 1464-1480.) and applied to the analysis of gene expression data from microarrays.
- the clustering method is similar to k-means clustering (Kaech, S. M.
- LC319 cells expressing GHSRlb and NTSRl were cultured in the presence of NMU-25 or BSA (control) at final concentrations of 100 ⁇ M in the culture media.
- NMU-25-treated cells showed higher expression of FOXMl compared to the control cells ( Figure 15c).
- FOXMl was also confirmed to be up-regulated in LC319 cells expressing exogenous NMU, compared with that of control cells transfected with mock vector (data not shown).
- NMU by the interaction with GHSRlb/NTSRl and subsequent activation of its downstream targets, such as FOXMl, could significantly affect the growth of lung-cancer cells.
- FOXMl transcription factor is a downstream target of ⁇ MU signaling by additional biological assays.
- FOXMl was known to be over-expressed in several types of human cancers (Teh, M.T.
- the "forkhead' gene family originally identified in Drosophila, comprises transcription factors with a conserved 100-amino acid D ⁇ A-binding motif, and has been shown to play important roles in regulating the expression of genes involved in cell growth, proliferation, differentiation, longevity, and transformation.
- NMU is a secreted protein and most of the clinical NSCLC samples used for our analysis were at an early and operable stage, NMU might serve as a biomarker for diagnosis of early-stage lung cancer, in combination with fiberscopic transbronchial biopsy (TBB) or blood tests.
- TTB fiberscopic transbronchial biopsy
- each of KIFll, KOCl, GHSRlb, NTSRl and FOXMl proteins stimulate oncogenic activity.
- each of these oncoproteins is a useful target for the development of anti-cancer pharmaceuticals.
- agents that block the expression of KIFll, KOCl, GHSRlb, NTSRl or FOXMl, or prevent its activity may find therapeutic utility as anti-cancer agents, particularly anti-cancer agents for the treatment of NSCLC.
- agents include antisense oligonucleotides, small interfering RNAs, and ribozymes against the KIFl 1, KOCl, GHSRlb, NTSRl or FOXMl gene, and antibodies that recognize KIFll, KOCl, GHSRlb, NTSRl or FOXMl polypeptide.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602005025998T DE602005025998D1 (en) | 2004-03-23 | 2005-03-18 | METHOD FOR THE DIAGNOSIS OF NON-SMALL CELLULOSE CANCER |
EP05721540A EP1737979B9 (en) | 2004-03-23 | 2005-03-18 | Method for diagnosing non-small cell lung cancer |
CN2005800165605A CN1977052B (en) | 2004-03-23 | 2005-03-18 | Double-chain molecule and vector related with KIF 11 gene |
JP2006526453A JP4938451B2 (en) | 2004-03-23 | 2005-03-18 | Methods for diagnosis of non-small cell lung cancer |
US10/593,842 US7700573B2 (en) | 2004-03-23 | 2005-03-18 | Method for diagnosing non-small lung cancer |
AT05721540T ATE496142T1 (en) | 2004-03-23 | 2005-03-18 | METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER |
US12/700,669 US7972772B2 (en) | 2004-03-23 | 2010-02-04 | KIF11 and method for diagnosing non-small cell lung cancer |
US13/113,732 US20110223687A1 (en) | 2004-03-23 | 2011-05-23 | Method for diagnosing non-small cell lung cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55578904P | 2004-03-23 | 2004-03-23 | |
US60/555,789 | 2004-03-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/593,842 A-371-Of-International US7700573B2 (en) | 2004-03-23 | 2005-03-18 | Method for diagnosing non-small lung cancer |
US12/700,669 Division US7972772B2 (en) | 2004-03-23 | 2010-02-04 | KIF11 and method for diagnosing non-small cell lung cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005090603A2 true WO2005090603A2 (en) | 2005-09-29 |
WO2005090603A3 WO2005090603A3 (en) | 2006-03-02 |
Family
ID=34961862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/005613 WO2005090603A2 (en) | 2004-03-23 | 2005-03-18 | Method for diagnosing non-small cell lung cancer |
Country Status (9)
Country | Link |
---|---|
US (3) | US7700573B2 (en) |
EP (2) | EP2343384A3 (en) |
JP (2) | JP4938451B2 (en) |
CN (1) | CN1977052B (en) |
AT (1) | ATE496142T1 (en) |
DE (1) | DE602005025998D1 (en) |
ES (1) | ES2360073T3 (en) |
TW (1) | TW200600785A (en) |
WO (1) | WO2005090603A2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007097469A1 (en) * | 2006-02-24 | 2007-08-30 | Oncotherapy Science, Inc. | A dominant negative peptide of imp-3, polynucleotide encoding the same, pharmaceutical composition containing the same, and methods for treating or preventing cancer |
WO2007123247A1 (en) * | 2006-04-20 | 2007-11-01 | Oncotherapy Science, Inc. | NMU-GHSR1b/NTSR1 ONCOGENIC SIGNALING PATHWAY AS A THERAPEUTIC TARGET FOR LUNG CANCER |
WO2008023840A2 (en) * | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
WO2008033782A3 (en) * | 2006-09-12 | 2008-07-03 | Genentech Inc | Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker |
WO2009025196A1 (en) * | 2007-08-20 | 2009-02-26 | Oncotherapy Science, Inc. | Foxm1 peptide and medicinal agent comprising the same |
WO2009028580A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
WO2009028521A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis |
WO2009028581A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
WO2009127619A1 (en) * | 2008-04-16 | 2009-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment, the prognostic assessment and the staging of non-small cell lung cancer |
EP2145964A1 (en) * | 2008-07-17 | 2010-01-20 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
JP2010501162A (en) * | 2006-08-18 | 2010-01-21 | オンコセラピー・サイエンス株式会社 | IMP-1 oncogene as a therapeutic target and prognostic indicator for lung cancer |
WO2010007791A1 (en) * | 2008-07-16 | 2010-01-21 | Oncotherapy Science, Inc. | Ect2 oncogene as a therapeutic target and prognostic indicator for lung and esophageal cancer |
WO2010037856A2 (en) * | 2008-10-03 | 2010-04-08 | Stichting Katholieke Universiteit, Universitair Medisch Centrum St. Radboud | DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS |
WO2010079158A1 (en) * | 2009-01-07 | 2010-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment, the prognostic assessment and the detection of breast cancer |
EP2295602A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
EP2350276A1 (en) * | 2008-08-27 | 2011-08-03 | Oncotherapy Science, Inc. | Syngr4 for target genes of cancer therapy and diagnosis |
US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
GB2496150A (en) * | 2011-11-02 | 2013-05-08 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Biomarker and target for responsiveness and resistance to cancer targeting agents |
EP2650683A1 (en) * | 2007-06-29 | 2013-10-16 | Abbott Laboratories | Methods and marker combinations for screening for predisposition to lung cancer |
US8614176B2 (en) | 2005-02-25 | 2013-12-24 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides |
US8617562B2 (en) | 2009-02-18 | 2013-12-31 | Oncotherapy Science, Inc. | FOXM1 peptides and immunogenic compositions containing them |
US9770498B2 (en) | 2013-05-24 | 2017-09-26 | Oncotherapy Science, Inc. | IMP-3 epitope peptides for TH1 cells and vaccines containing the same |
US9933429B2 (en) | 2007-09-11 | 2018-04-03 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof |
US10576102B2 (en) | 2014-08-04 | 2020-03-03 | Oncotherapy Science, Inc. | KOC1-derived peptide and vaccine including same |
EP3035935B1 (en) * | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
US11242365B2 (en) | 2015-10-08 | 2022-02-08 | Oncotherapy Science, Inc. | FOXM1-derived peptide, and vaccine including same |
US11474104B2 (en) | 2009-03-12 | 2022-10-18 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy |
US11769596B2 (en) | 2017-04-04 | 2023-09-26 | Lung Cancer Proteomics Llc | Plasma based protein profiling for early stage lung cancer diagnosis |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
US20070082845A1 (en) * | 2005-07-15 | 2007-04-12 | The Penn State Research Foundation | Ferritin as a therapeutic target in abnormal cells |
EP2363205A3 (en) | 2006-01-11 | 2014-06-04 | Raindance Technologies, Inc. | Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors |
ATE540750T1 (en) | 2006-05-11 | 2012-01-15 | Raindance Technologies Inc | MICROFLUIDIC DEVICE AND METHOD |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
EP3536396B1 (en) | 2006-08-07 | 2022-03-30 | The President and Fellows of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
EP2060583A1 (en) * | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
US9783857B2 (en) | 2007-11-30 | 2017-10-10 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
US9797017B2 (en) | 2007-11-30 | 2017-10-24 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
US10113203B2 (en) | 2007-11-30 | 2018-10-30 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
US9670552B2 (en) | 2007-11-30 | 2017-06-06 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
US9670551B2 (en) | 2007-11-30 | 2017-06-06 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
CN102912019B (en) | 2007-11-30 | 2016-03-23 | 基因特力株式会社 | Use bladder cancer diagnosis agent box and the chip of bladder cancer specific methylation marker gene |
EP2297581B1 (en) * | 2008-07-03 | 2013-04-03 | F. Hoffmann-La Roche AG | Asc as a marker for lung cancer |
EP2315629B1 (en) | 2008-07-18 | 2021-12-15 | Bio-Rad Laboratories, Inc. | Droplet libraries |
CA3152591C (en) * | 2008-09-09 | 2023-08-29 | Somalogic Operating Co., Inc. | Lung cancer biomarkers and uses thereof |
WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
JP5934657B2 (en) | 2010-02-12 | 2016-06-15 | レインダンス テクノロジーズ, インコーポレイテッド | Digital specimen analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
EP3447155A1 (en) | 2010-09-30 | 2019-02-27 | Raindance Technologies, Inc. | Sandwich assays in droplets |
EP3412778A1 (en) | 2011-02-11 | 2018-12-12 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
EP2675819B1 (en) | 2011-02-18 | 2020-04-08 | Bio-Rad Laboratories, Inc. | Compositions and methods for molecular labeling |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
DE202012013668U1 (en) | 2011-06-02 | 2019-04-18 | Raindance Technologies, Inc. | enzyme quantification |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
US20130158023A1 (en) * | 2011-08-03 | 2013-06-20 | Signal Pharmaceuticals, Llc | Identification of gene expression as a predictive biomarker for lkb1 status |
US20130210659A1 (en) | 2012-02-10 | 2013-08-15 | Andrew Watson | Molecular diagnostic screening assay |
EP3524693A1 (en) | 2012-04-30 | 2019-08-14 | Raindance Technologies, Inc. | Digital analyte analysis |
WO2014144129A2 (en) * | 2013-03-15 | 2014-09-18 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
JP2014207883A (en) * | 2013-03-27 | 2014-11-06 | 国立大学法人岡山大学 | Cancer stem cell and application thereof |
WO2014172288A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc. | Digital analyte analysis |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
EP3090063B1 (en) | 2013-12-31 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Method for detection of latent retrovirus |
BR112017027528A2 (en) | 2015-06-19 | 2018-09-11 | Sera Prognostics, Inc. | composition, panel, method for determining the likelihood of preterm birth in a pregnant female and method of detecting ibp4 and shbg in a pregnant female? |
CN107828871A (en) * | 2015-06-24 | 2018-03-23 | 湖北工业大学 | The detection reagent that FoxM1 genes P271Q is mutated in Wnt signal paths based on peptide nucleic acid probe |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
WO2018017144A1 (en) * | 2016-07-19 | 2018-01-25 | Brandeis University | Compositions and methods for identifying rna binding polypeptide targets |
EP3668996A4 (en) | 2017-08-18 | 2021-04-21 | Sera Prognostics, Inc. | Pregnancy clock proteins for predicting due date and time to birth |
US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
CN111317743B (en) * | 2020-03-13 | 2022-11-29 | 中国人民解放军第四军医大学 | Application of recombinant adeno-associated virus based on Kif11 gene in inhibition of pathological pain |
TWI781647B (en) * | 2020-06-09 | 2022-10-21 | 財團法人國家衛生研究院 | Anti-human neurotensin receptor 1 antibody and use thereof |
CN114561358B (en) * | 2022-03-09 | 2023-10-03 | 广州源井生物科技有限公司 | Enhanced infection culture medium and method for improving infection rate of cell lentivirus |
CN115478106B (en) * | 2022-08-18 | 2023-07-07 | 南方医科大学南方医院 | LR-based method for typing triple negative breast cancer and application thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JPH07509137A (en) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | Production of xenoantibodies |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5889170A (en) * | 1997-01-31 | 1999-03-30 | Incyte Pharmaceuticals, Inc. | Human integral membrane protein |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6297364B1 (en) * | 1998-04-17 | 2001-10-02 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof |
US20020103360A1 (en) | 1998-09-01 | 2002-08-01 | Yang Pan | Novel protein related to melanoma-inhibiting protein and uses thereof |
CA2348003A1 (en) * | 1998-09-23 | 2000-04-20 | Cleveland Clinic Foundation | Novel interferon stimulated and repressed genes |
AU4367700A (en) * | 1999-04-20 | 2000-11-02 | Cytokinetics, Inc. | Human kinesins and methods of producing and purifying human kinesins |
DE19935303A1 (en) * | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonucleotides to inhibit the expression of human eg5 |
US6617115B1 (en) * | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
EP1358349A2 (en) * | 2000-06-05 | 2003-11-05 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
US7358353B2 (en) * | 2000-08-22 | 2008-04-15 | Agensys, Inc. | Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
US6706867B1 (en) * | 2000-12-19 | 2004-03-16 | The United States Of America As Represented By The Department Of Health And Human Services | DNA array sequence selection |
US20020165240A1 (en) * | 2001-03-29 | 2002-11-07 | Kimball Spencer David | Method of treating proliferative diseases using Eg5 inhibitors |
DE60234467D1 (en) * | 2001-08-16 | 2009-12-31 | Us Health | MOLECULAR PROPERTIES OF NON-SMALL CELL LUNG CANCER |
US20040009156A1 (en) * | 2001-10-12 | 2004-01-15 | Christoph Reinhard | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer |
US7163927B2 (en) * | 2002-05-23 | 2007-01-16 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
CA2543954C (en) * | 2003-10-27 | 2016-11-08 | Rosetta Inpharmatics Llc | Method of designing sirnas for gene silencing |
WO2005076979A2 (en) * | 2004-02-06 | 2005-08-25 | Wyeth | Diagnosis and therapeutics for cancer |
-
2005
- 2005-03-18 EP EP10177195A patent/EP2343384A3/en not_active Withdrawn
- 2005-03-18 DE DE602005025998T patent/DE602005025998D1/en active Active
- 2005-03-18 CN CN2005800165605A patent/CN1977052B/en not_active Expired - Fee Related
- 2005-03-18 JP JP2006526453A patent/JP4938451B2/en not_active Expired - Fee Related
- 2005-03-18 TW TW094108342A patent/TW200600785A/en unknown
- 2005-03-18 WO PCT/JP2005/005613 patent/WO2005090603A2/en active Application Filing
- 2005-03-18 AT AT05721540T patent/ATE496142T1/en not_active IP Right Cessation
- 2005-03-18 ES ES05721540T patent/ES2360073T3/en active Active
- 2005-03-18 US US10/593,842 patent/US7700573B2/en not_active Expired - Fee Related
- 2005-03-18 EP EP05721540A patent/EP1737979B9/en not_active Not-in-force
-
2010
- 2010-02-04 US US12/700,669 patent/US7972772B2/en not_active Expired - Fee Related
- 2010-09-24 JP JP2010212951A patent/JP2011039069A/en not_active Withdrawn
-
2011
- 2011-05-23 US US13/113,732 patent/US20110223687A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
KIKUCHI, T., ONCOGENE, vol. 22, 2003, pages 2192 - 2205 |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8685641B2 (en) | 2005-02-10 | 2014-04-01 | Oncotherapy Science, Inc. | Method of screening compounds for treating bladder cancer |
US7998695B2 (en) | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
US8614176B2 (en) | 2005-02-25 | 2013-12-24 | Oncotherapy Science, Inc. | Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides |
EP2298933A1 (en) | 2005-07-27 | 2011-03-23 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
EP2311986A1 (en) | 2005-07-27 | 2011-04-20 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
EP2295602A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
EP2311985A1 (en) | 2005-07-27 | 2011-04-20 | Oncotherapy Science, Inc. | Sirna for treating esophageal cancer |
US9347945B2 (en) | 2005-12-22 | 2016-05-24 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
WO2007097469A1 (en) * | 2006-02-24 | 2007-08-30 | Oncotherapy Science, Inc. | A dominant negative peptide of imp-3, polynucleotide encoding the same, pharmaceutical composition containing the same, and methods for treating or preventing cancer |
WO2007123247A1 (en) * | 2006-04-20 | 2007-11-01 | Oncotherapy Science, Inc. | NMU-GHSR1b/NTSR1 ONCOGENIC SIGNALING PATHWAY AS A THERAPEUTIC TARGET FOR LUNG CANCER |
JP2010501162A (en) * | 2006-08-18 | 2010-01-21 | オンコセラピー・サイエンス株式会社 | IMP-1 oncogene as a therapeutic target and prognostic indicator for lung cancer |
WO2008023840A3 (en) * | 2006-08-25 | 2008-07-17 | Oncotherapy Science Inc | Prognostic markers and therapeutic targets for lung cancer |
EP2423333A1 (en) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
JP2010501172A (en) * | 2006-08-25 | 2010-01-21 | オンコセラピー・サイエンス株式会社 | Prognostic markers and therapeutic targets for lung cancer |
EP2423332A1 (en) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
WO2008023840A2 (en) * | 2006-08-25 | 2008-02-28 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
WO2008033782A3 (en) * | 2006-09-12 | 2008-07-03 | Genentech Inc | Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker |
EP2650683A1 (en) * | 2007-06-29 | 2013-10-16 | Abbott Laboratories | Methods and marker combinations for screening for predisposition to lung cancer |
EP3270164A1 (en) * | 2007-06-29 | 2018-01-17 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
US9073968B2 (en) | 2007-08-20 | 2015-07-07 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
US8569244B2 (en) | 2007-08-20 | 2013-10-29 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
JP5555952B2 (en) * | 2007-08-20 | 2014-07-23 | オンコセラピー・サイエンス株式会社 | FOXM1 peptide and drug containing the same |
CN101835792A (en) * | 2007-08-20 | 2010-09-15 | 肿瘤疗法科学股份有限公司 | FOXM1 peptide and medicinal agent comprising the same |
EP4032899A1 (en) * | 2007-08-20 | 2022-07-27 | Oncotherapy Science, Inc. | Foxm1 peptide and medicinal agent comprising the same |
CN104774261A (en) * | 2007-08-20 | 2015-07-15 | 肿瘤疗法科学股份有限公司 | FOXM1 peptide and medicinal agent comprising the same |
JP2014193893A (en) * | 2007-08-20 | 2014-10-09 | Oncotherapy Science Ltd | Foxm1 peptide and medicinal agent comprising the same |
CN104774261B (en) * | 2007-08-20 | 2018-03-06 | 肿瘤疗法科学股份有限公司 | FOXM1 peptides and the medicament for including FOXM1 peptides |
EP3263585A3 (en) * | 2007-08-20 | 2018-02-28 | Oncotherapy Science, Inc. | Foxm1 peptide and medicinal agent comprising the same |
AU2008290049B2 (en) * | 2007-08-20 | 2013-08-29 | Oncotherapy Science, Inc. | FOXM1 peptide and medicinal agent comprising the same |
JPWO2009025196A1 (en) * | 2007-08-20 | 2010-11-25 | オンコセラピー・サイエンス株式会社 | FOXM1 peptide and drug containing the same |
WO2009025196A1 (en) * | 2007-08-20 | 2009-02-26 | Oncotherapy Science, Inc. | Foxm1 peptide and medicinal agent comprising the same |
US9415096B2 (en) | 2007-08-20 | 2016-08-16 | OncoTherapy Sciences, Inc. | FOXM1 peptide and medicinal agent comprising the same |
WO2009028580A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
EP2198021A1 (en) * | 2007-08-24 | 2010-06-23 | Oncotherapy Science, Inc. | Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
WO2009028521A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis |
WO2009028581A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Cancer-related genes, cdca5, epha7, stk31 and wdhd1 |
EP2198021A4 (en) * | 2007-08-24 | 2011-01-19 | Oncotherapy Science Inc | Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis |
US9933429B2 (en) | 2007-09-11 | 2018-04-03 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof |
US8529900B2 (en) | 2008-04-16 | 2013-09-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment, the prognostic assessment and the staging of non-small cell lung cancer |
WO2009127619A1 (en) * | 2008-04-16 | 2009-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment, the prognostic assessment and the staging of non-small cell lung cancer |
WO2010007791A1 (en) * | 2008-07-16 | 2010-01-21 | Oncotherapy Science, Inc. | Ect2 oncogene as a therapeutic target and prognostic indicator for lung and esophageal cancer |
WO2010007093A1 (en) * | 2008-07-17 | 2010-01-21 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
EP2145964A1 (en) * | 2008-07-17 | 2010-01-20 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
EP2350276A4 (en) * | 2008-08-27 | 2012-07-25 | Oncotherapy Science Inc | Syngr4 for target genes of cancer therapy and diagnosis |
EP2350276A1 (en) * | 2008-08-27 | 2011-08-03 | Oncotherapy Science, Inc. | Syngr4 for target genes of cancer therapy and diagnosis |
WO2010037856A3 (en) * | 2008-10-03 | 2010-06-24 | Stichting Katholieke Universiteit, Universitair Medisch Centrum St. Radboud | DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS |
WO2010037856A2 (en) * | 2008-10-03 | 2010-04-08 | Stichting Katholieke Universiteit, Universitair Medisch Centrum St. Radboud | DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS |
WO2010079158A1 (en) * | 2009-01-07 | 2010-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment, the prognostic assessment and the detection of breast cancer |
US8586043B2 (en) | 2009-01-07 | 2013-11-19 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1 |
US8617562B2 (en) | 2009-02-18 | 2013-12-31 | Oncotherapy Science, Inc. | FOXM1 peptides and immunogenic compositions containing them |
US11474104B2 (en) | 2009-03-12 | 2022-10-18 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy |
GB2496150A (en) * | 2011-11-02 | 2013-05-08 | Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin | Biomarker and target for responsiveness and resistance to cancer targeting agents |
US9770498B2 (en) | 2013-05-24 | 2017-09-26 | Oncotherapy Science, Inc. | IMP-3 epitope peptides for TH1 cells and vaccines containing the same |
EP3035935B1 (en) * | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
US10576102B2 (en) | 2014-08-04 | 2020-03-03 | Oncotherapy Science, Inc. | KOC1-derived peptide and vaccine including same |
US11547723B2 (en) | 2014-08-04 | 2023-01-10 | Oncotherapy Science, Inc. | KOC1-derived peptide and vaccine including same |
US11242365B2 (en) | 2015-10-08 | 2022-02-08 | Oncotherapy Science, Inc. | FOXM1-derived peptide, and vaccine including same |
EP4219525A2 (en) | 2015-10-08 | 2023-08-02 | OncoTherapy Science, Inc. | Foxm1-derived peptide, and vaccine including same |
US11769596B2 (en) | 2017-04-04 | 2023-09-26 | Lung Cancer Proteomics Llc | Plasma based protein profiling for early stage lung cancer diagnosis |
Also Published As
Publication number | Publication date |
---|---|
EP1737979B1 (en) | 2011-01-19 |
US7972772B2 (en) | 2011-07-05 |
WO2005090603A3 (en) | 2006-03-02 |
ES2360073T3 (en) | 2011-05-31 |
JP2011039069A (en) | 2011-02-24 |
TW200600785A (en) | 2006-01-01 |
EP2343384A3 (en) | 2012-01-04 |
JP4938451B2 (en) | 2012-05-23 |
JP2007530006A (en) | 2007-11-01 |
US20100173317A1 (en) | 2010-07-08 |
US7700573B2 (en) | 2010-04-20 |
EP1737979A2 (en) | 2007-01-03 |
CN1977052A (en) | 2007-06-06 |
ATE496142T1 (en) | 2011-02-15 |
US20080050378A1 (en) | 2008-02-28 |
EP2343384A2 (en) | 2011-07-13 |
DE602005025998D1 (en) | 2011-03-03 |
CN1977052B (en) | 2012-09-05 |
EP1737979B9 (en) | 2011-09-21 |
US20110223687A1 (en) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7700573B2 (en) | Method for diagnosing non-small lung cancer | |
CN1890381B (en) | Method of diagnosing breast cancer | |
US20070054849A1 (en) | Method for diagnosing hepatocellular carcinomas | |
JP2009502115A (en) | Diagnostic method for small cell lung cancer | |
EP1907580A2 (en) | Method for diagnosing and treating renal cell carcinoma | |
WO2004031413A9 (en) | Method for diagnosing non-small cell lung cancers | |
WO2006085684A9 (en) | Method of diagnosing bladder cancer | |
US8029981B2 (en) | Hypoxia-inducible protein 2 (HIG2), a diagnostic marker for clear cell renal cell carcinoma | |
WO2007013360A2 (en) | Pancreatic cancer related gene cst6 and gabrp | |
EP1915462A2 (en) | Cancer related gene rasgef1a | |
US20080199468A1 (en) | Method For Diagnosing Colorectal Cancers | |
WO2005090398A1 (en) | Genes and polypeptides relating to prostate cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006526453 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005721540 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580016560.5 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005721540 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10593842 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10593842 Country of ref document: US |